CN115461061A - Genetically modified T cells and uses thereof - Google Patents
Genetically modified T cells and uses thereof Download PDFInfo
- Publication number
- CN115461061A CN115461061A CN202080083339.6A CN202080083339A CN115461061A CN 115461061 A CN115461061 A CN 115461061A CN 202080083339 A CN202080083339 A CN 202080083339A CN 115461061 A CN115461061 A CN 115461061A
- Authority
- CN
- China
- Prior art keywords
- recombinant
- cells
- car
- cell
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 174
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 146
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 143
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 48
- 230000011664 signaling Effects 0.000 claims abstract description 33
- 108091008034 costimulatory receptors Proteins 0.000 claims abstract description 31
- 230000004068 intracellular signaling Effects 0.000 claims abstract description 30
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 24
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 claims abstract description 16
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 claims abstract description 16
- 239000012634 fragment Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 129
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 80
- 150000007523 nucleic acids Chemical class 0.000 claims description 58
- 102000039446 nucleic acids Human genes 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 54
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 37
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 30
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 7
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 5
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 61
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 61
- 230000014509 gene expression Effects 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 32
- 230000003211 malignant effect Effects 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 21
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 108091008874 T cell receptors Proteins 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 14
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 14
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 12
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 239000012636 effector Substances 0.000 description 12
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- -1 EST Substances 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 230000009977 dual effect Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 210000003071 memory t lymphocyte Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 7
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 7
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 6
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 6
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 108010087924 alanylproline Proteins 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 108010010147 glycylglutamine Proteins 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 description 5
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 5
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 5
- JESJDAAGXULQOP-CIUDSAMLSA-N Gln-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N JESJDAAGXULQOP-CIUDSAMLSA-N 0.000 description 5
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 5
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010079364 N-glycylalanine Proteins 0.000 description 5
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000005909 tumor killing Effects 0.000 description 5
- 108010073969 valyllysine Proteins 0.000 description 5
- 208000003200 Adenoma Diseases 0.000 description 4
- AWAXZRDKUHOPBO-GUBZILKMSA-N Ala-Gln-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O AWAXZRDKUHOPBO-GUBZILKMSA-N 0.000 description 4
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 4
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 4
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 4
- ANRZCQXIXGDXLR-CWRNSKLLSA-N Asn-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC(=O)N)N)C(=O)O ANRZCQXIXGDXLR-CWRNSKLLSA-N 0.000 description 4
- MLJZMGIXXMTEPO-UBHSHLNASA-N Asn-Trp-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O MLJZMGIXXMTEPO-UBHSHLNASA-N 0.000 description 4
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 4
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 4
- OJNZVYSGVYLQIN-BQBZGAKWSA-N Gly-Met-Asp Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O OJNZVYSGVYLQIN-BQBZGAKWSA-N 0.000 description 4
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 4
- ISHNZELVUVPCHY-ZETCQYMHSA-N Lys-Gly-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O ISHNZELVUVPCHY-ZETCQYMHSA-N 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 4
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 4
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 4
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 4
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 4
- ONNSECRQFSTMCC-XKBZYTNZSA-N Thr-Glu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ONNSECRQFSTMCC-XKBZYTNZSA-N 0.000 description 4
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 4
- YRJOLUDFVAUXLI-GSSVUCPTSA-N Thr-Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O YRJOLUDFVAUXLI-GSSVUCPTSA-N 0.000 description 4
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 4
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 4
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 4
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 108010060199 cysteinylproline Proteins 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000012642 immune effector Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- SSSROGPPPVTHLX-FXQIFTODSA-N Ala-Arg-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSROGPPPVTHLX-FXQIFTODSA-N 0.000 description 3
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 3
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 3
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 3
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 3
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 3
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 3
- YNSCBOUZTAGIGO-ZLUOBGJFSA-N Asn-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)N YNSCBOUZTAGIGO-ZLUOBGJFSA-N 0.000 description 3
- KZYSHAMXEBPJBD-JRQIVUDYSA-N Asn-Thr-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZYSHAMXEBPJBD-JRQIVUDYSA-N 0.000 description 3
- AMRANMVXQWXNAH-ZLUOBGJFSA-N Asp-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC(O)=O AMRANMVXQWXNAH-ZLUOBGJFSA-N 0.000 description 3
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 238000011357 CAR T-cell therapy Methods 0.000 description 3
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- HJGUQJJJXQGXGJ-FXQIFTODSA-N Cys-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N HJGUQJJJXQGXGJ-FXQIFTODSA-N 0.000 description 3
- LLUXQOVDMQZMPJ-KKUMJFAQSA-N Cys-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CS)CC1=CC=C(O)C=C1 LLUXQOVDMQZMPJ-KKUMJFAQSA-N 0.000 description 3
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 3
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 description 3
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 3
- SXGMGNZEHFORAV-IUCAKERBSA-N Gln-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N SXGMGNZEHFORAV-IUCAKERBSA-N 0.000 description 3
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 3
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 3
- ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 3
- NKSGKPWXSWBRRX-ACZMJKKPSA-N Glu-Asn-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N NKSGKPWXSWBRRX-ACZMJKKPSA-N 0.000 description 3
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 3
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 3
- FKJQNJCQTKUBCD-XPUUQOCRSA-N Gly-Ala-His Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O FKJQNJCQTKUBCD-XPUUQOCRSA-N 0.000 description 3
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 3
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 3
- IALQAMYQJBZNSK-WHFBIAKZSA-N Gly-Ser-Asn Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O IALQAMYQJBZNSK-WHFBIAKZSA-N 0.000 description 3
- WTUSRDZLLWGYAT-KCTSRDHCSA-N Gly-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)CN WTUSRDZLLWGYAT-KCTSRDHCSA-N 0.000 description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 3
- DYKZGTLPSNOFHU-DEQVHRJGSA-N His-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N DYKZGTLPSNOFHU-DEQVHRJGSA-N 0.000 description 3
- SWTSERYNZQMPBI-WDSOQIARSA-N His-Trp-Met Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(O)=O)C1=CN=CN1 SWTSERYNZQMPBI-WDSOQIARSA-N 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 3
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 3
- JBRWKVANRYPCAF-XIRDDKMYSA-N Lys-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N JBRWKVANRYPCAF-XIRDDKMYSA-N 0.000 description 3
- LLSUNJYOSCOOEB-GUBZILKMSA-N Lys-Glu-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O LLSUNJYOSCOOEB-GUBZILKMSA-N 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 description 3
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 3
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 3
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 3
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 3
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 3
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 3
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 3
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 3
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 3
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- FQNUWOHNGJWNLM-QWRGUYRKSA-N Tyr-Cys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FQNUWOHNGJWNLM-QWRGUYRKSA-N 0.000 description 3
- FXYOYUMPUJONGW-FHWLQOOXSA-N Tyr-Gln-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 FXYOYUMPUJONGW-FHWLQOOXSA-N 0.000 description 3
- ZRPLVTZTKPPSBT-AVGNSLFASA-N Tyr-Glu-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZRPLVTZTKPPSBT-AVGNSLFASA-N 0.000 description 3
- PHKQVWWHRYUCJL-HJOGWXRNSA-N Tyr-Phe-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PHKQVWWHRYUCJL-HJOGWXRNSA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 3
- USXYVSTVPHELAF-RCWTZXSCSA-N Val-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N)O USXYVSTVPHELAF-RCWTZXSCSA-N 0.000 description 3
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 3
- VBTFUDNTMCHPII-UHFFFAOYSA-N Val-Trp-Tyr Natural products C=1NC2=CC=CC=C2C=1CC(NC(=O)C(N)C(C)C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 VBTFUDNTMCHPII-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108010081404 acein-2 Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 108010069495 cysteinyltyrosine Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 3
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 102000027596 immune receptors Human genes 0.000 description 3
- 108091008915 immune receptors Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 108010005942 methionylglycine Proteins 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000010473 stable expression Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108010044292 tryptophyltyrosine Proteins 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 2
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 2
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 2
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 2
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 2
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 2
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 2
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 2
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 2
- UPAGTDJAORYMEC-VHWLVUOQSA-N Asn-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)N)N UPAGTDJAORYMEC-VHWLVUOQSA-N 0.000 description 2
- DGKCOYGQLNWNCJ-ACZMJKKPSA-N Asp-Glu-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DGKCOYGQLNWNCJ-ACZMJKKPSA-N 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- 201000000274 Carcinosarcoma Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- JTNKVWLMDHIUOG-IHRRRGAJSA-N Cys-Arg-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JTNKVWLMDHIUOG-IHRRRGAJSA-N 0.000 description 2
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 2
- KABHAOSDMIYXTR-GUBZILKMSA-N Cys-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N KABHAOSDMIYXTR-GUBZILKMSA-N 0.000 description 2
- PGBLJHDDKCVSTC-CIUDSAMLSA-N Cys-Met-Gln Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O PGBLJHDDKCVSTC-CIUDSAMLSA-N 0.000 description 2
- HMWBPUDETPKSSS-DCAQKATOSA-N Cys-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CS)N)C(=O)N[C@@H](CCCCN)C(=O)O HMWBPUDETPKSSS-DCAQKATOSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 2
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 2
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 2
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 2
- BZULIEARJFRINC-IHRRRGAJSA-N Gln-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BZULIEARJFRINC-IHRRRGAJSA-N 0.000 description 2
- XQDGOJPVMSWZSO-SRVKXCTJSA-N Gln-Pro-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)N)N XQDGOJPVMSWZSO-SRVKXCTJSA-N 0.000 description 2
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 2
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 2
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 2
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 2
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 2
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 2
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 2
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 2
- TVSPLSZTKTUYLV-ZPFDUUQYSA-N Ile-Glu-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O TVSPLSZTKTUYLV-ZPFDUUQYSA-N 0.000 description 2
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 2
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 2
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 2
- ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 2
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 206010024612 Lipoma Diseases 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 2
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 2
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 2
- YRNRVKTYDSLKMD-KKUMJFAQSA-N Lys-Ser-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YRNRVKTYDSLKMD-KKUMJFAQSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- MRNRMSDVVSKPGM-AVGNSLFASA-N Phe-Asn-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MRNRMSDVVSKPGM-AVGNSLFASA-N 0.000 description 2
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 2
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 2
- DSGSTPRKNYHGCL-JYJNAYRXSA-N Pro-Phe-Met Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O DSGSTPRKNYHGCL-JYJNAYRXSA-N 0.000 description 2
- YYARMJSFDLIDFS-FKBYEOEOSA-N Pro-Phe-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YYARMJSFDLIDFS-FKBYEOEOSA-N 0.000 description 2
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 2
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 2
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- NAXBBCLCEOTAIG-RHYQMDGZSA-N Thr-Arg-Lys Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O NAXBBCLCEOTAIG-RHYQMDGZSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 2
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 2
- LJCLHMPCYYXVPR-VJBMBRPKSA-N Trp-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N LJCLHMPCYYXVPR-VJBMBRPKSA-N 0.000 description 2
- VDCGPCSLAJAKBB-XIRDDKMYSA-N Trp-Ser-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N VDCGPCSLAJAKBB-XIRDDKMYSA-N 0.000 description 2
- WGBFZZYIWFSYER-BVSLBCMMSA-N Trp-Val-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N WGBFZZYIWFSYER-BVSLBCMMSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- LQGDFDYGDQEMGA-PXDAIIFMSA-N Tyr-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N LQGDFDYGDQEMGA-PXDAIIFMSA-N 0.000 description 2
- CDKZJGMPZHPAJC-ULQDDVLXSA-N Tyr-Leu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CDKZJGMPZHPAJC-ULQDDVLXSA-N 0.000 description 2
- QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 229960000578 gemtuzumab Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 108010027338 isoleucylcysteine Proteins 0.000 description 2
- 108010078274 isoleucylvaline Proteins 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical group C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- WJRXVTCKASUIFF-FXQIFTODSA-N Ala-Cys-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WJRXVTCKASUIFF-FXQIFTODSA-N 0.000 description 1
- YIGLXQRFQVWFEY-NRPADANISA-N Ala-Gln-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O YIGLXQRFQVWFEY-NRPADANISA-N 0.000 description 1
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 1
- RUXQNKVQSKOOBS-JURCDPSOSA-N Ala-Phe-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RUXQNKVQSKOOBS-JURCDPSOSA-N 0.000 description 1
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- TTXYKSADPSNOIF-IHRRRGAJSA-N Arg-Asp-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O TTXYKSADPSNOIF-IHRRRGAJSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- JCROZIFVIYMXHM-GUBZILKMSA-N Arg-Met-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N JCROZIFVIYMXHM-GUBZILKMSA-N 0.000 description 1
- INXWADWANGLMPJ-JYJNAYRXSA-N Arg-Phe-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CC1=CC=CC=C1 INXWADWANGLMPJ-JYJNAYRXSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- XSPKAHFVDKRGRL-DCAQKATOSA-N Arg-Pro-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XSPKAHFVDKRGRL-DCAQKATOSA-N 0.000 description 1
- YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 1
- QHVRVUNEAIFTEK-SZMVWBNQSA-N Arg-Pro-Trp Chemical compound N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O QHVRVUNEAIFTEK-SZMVWBNQSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 1
- HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 1
- ZKDGORKGHPCZOV-DCAQKATOSA-N Asn-His-Arg Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZKDGORKGHPCZOV-DCAQKATOSA-N 0.000 description 1
- VCJCPARXDBEGNE-GUBZILKMSA-N Asn-Pro-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 VCJCPARXDBEGNE-GUBZILKMSA-N 0.000 description 1
- QUMKPKWYDVMGNT-NUMRIWBASA-N Asn-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QUMKPKWYDVMGNT-NUMRIWBASA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- BIVYLQMZPHDUIH-WHFBIAKZSA-N Asp-Gly-Cys Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)C(=O)O BIVYLQMZPHDUIH-WHFBIAKZSA-N 0.000 description 1
- RTXQQDVBACBSCW-CFMVVWHZSA-N Asp-Ile-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RTXQQDVBACBSCW-CFMVVWHZSA-N 0.000 description 1
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- JGLWFWXGOINXEA-YDHLFZDLSA-N Asp-Val-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JGLWFWXGOINXEA-YDHLFZDLSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 101150091609 CD274 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035984 Colonic Polyps Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- CVLIHKBUPSFRQP-WHFBIAKZSA-N Cys-Gly-Ala Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C)C(O)=O CVLIHKBUPSFRQP-WHFBIAKZSA-N 0.000 description 1
- UXIYYUMGFNSGBK-XPUUQOCRSA-N Cys-Gly-Val Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O UXIYYUMGFNSGBK-XPUUQOCRSA-N 0.000 description 1
- BCWIFCLVCRAIQK-ZLUOBGJFSA-N Cys-Ser-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O BCWIFCLVCRAIQK-ZLUOBGJFSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- DTMLKCYOQKZXKZ-HJGDQZAQSA-N Gln-Arg-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DTMLKCYOQKZXKZ-HJGDQZAQSA-N 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- KYFSMWLWHYZRNW-ACZMJKKPSA-N Gln-Asp-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N KYFSMWLWHYZRNW-ACZMJKKPSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- MTCXQQINVAFZKW-MNXVOIDGSA-N Gln-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MTCXQQINVAFZKW-MNXVOIDGSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- HHRAEXBUNGTOGZ-IHRRRGAJSA-N Gln-Phe-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O HHRAEXBUNGTOGZ-IHRRRGAJSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 1
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- QOXDAWODGSIDDI-GUBZILKMSA-N Glu-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N QOXDAWODGSIDDI-GUBZILKMSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- QCMVGXDELYMZET-GLLZPBPUSA-N Glu-Thr-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QCMVGXDELYMZET-GLLZPBPUSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- XXGQRGQPGFYECI-WDSKDSINSA-N Gly-Cys-Glu Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCC(O)=O XXGQRGQPGFYECI-WDSKDSINSA-N 0.000 description 1
- QCTLGOYODITHPQ-WHFBIAKZSA-N Gly-Cys-Ser Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O QCTLGOYODITHPQ-WHFBIAKZSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- CIWILNZNBPIHEU-DCAQKATOSA-N His-Arg-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O CIWILNZNBPIHEU-DCAQKATOSA-N 0.000 description 1
- FJCGVRRVBKYYOU-DCAQKATOSA-N His-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N FJCGVRRVBKYYOU-DCAQKATOSA-N 0.000 description 1
- XJFITURPHAKKAI-SRVKXCTJSA-N His-Pro-Gln Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CN=CN1 XJFITURPHAKKAI-SRVKXCTJSA-N 0.000 description 1
- YEKYGQZUBCRNGH-DCAQKATOSA-N His-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CO)C(=O)O YEKYGQZUBCRNGH-DCAQKATOSA-N 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- SRGRINJFBHKHAC-NAKRPEOUSA-N Ile-Cys-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)O)N SRGRINJFBHKHAC-NAKRPEOUSA-N 0.000 description 1
- SJLVSMMIFYTSGY-GRLWGSQLSA-N Ile-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SJLVSMMIFYTSGY-GRLWGSQLSA-N 0.000 description 1
- DMSVBUWGDLYNLC-IAVJCBSLSA-N Ile-Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DMSVBUWGDLYNLC-IAVJCBSLSA-N 0.000 description 1
- LRAUKBMYHHNADU-DKIMLUQUSA-N Ile-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 LRAUKBMYHHNADU-DKIMLUQUSA-N 0.000 description 1
- KLJKJVXDHVUMMZ-KKPKCPPISA-N Ile-Phe-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N KLJKJVXDHVUMMZ-KKPKCPPISA-N 0.000 description 1
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 1
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 1
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 1
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 1
- JTBFQNHKNRZJDS-SYWGBEHUSA-N Ile-Trp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)O)N JTBFQNHKNRZJDS-SYWGBEHUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 101150030732 KLRK1 gene Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 1
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 1
- JQSXWJXBASFONF-KKUMJFAQSA-N Leu-Asp-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JQSXWJXBASFONF-KKUMJFAQSA-N 0.000 description 1
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 1
- BGZCJDGBBUUBHA-KKUMJFAQSA-N Leu-Lys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O BGZCJDGBBUUBHA-KKUMJFAQSA-N 0.000 description 1
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 1
- NTXYXFDMIHXTHE-WDSOQIARSA-N Leu-Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 NTXYXFDMIHXTHE-WDSOQIARSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 1
- MQMIRLVJXQNTRJ-SDDRHHMPSA-N Lys-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O MQMIRLVJXQNTRJ-SDDRHHMPSA-N 0.000 description 1
- NNKLKUUGESXCBS-KBPBESRZSA-N Lys-Gly-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NNKLKUUGESXCBS-KBPBESRZSA-N 0.000 description 1
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- MHQXIBRPDKXDGZ-ZFWWWQNUSA-N Met-Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CNC(=O)[C@@H](N)CCSC)C(O)=O)=CNC2=C1 MHQXIBRPDKXDGZ-ZFWWWQNUSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000010357 Mullerian Mixed Tumor Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100404853 Mus musculus Klrk1 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 101150087384 PDCD1 gene Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 1
- DDYIRGBOZVKRFR-AVGNSLFASA-N Phe-Asp-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N DDYIRGBOZVKRFR-AVGNSLFASA-N 0.000 description 1
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 1
- MJAYDXWQQUOURZ-JYJNAYRXSA-N Phe-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MJAYDXWQQUOURZ-JYJNAYRXSA-N 0.000 description 1
- IEOHQGFKHXUALJ-JYJNAYRXSA-N Phe-Met-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IEOHQGFKHXUALJ-JYJNAYRXSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- BTAIJUBAGLVFKQ-BVSLBCMMSA-N Phe-Trp-Val Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=CC=C1 BTAIJUBAGLVFKQ-BVSLBCMMSA-N 0.000 description 1
- VIIRRNQMMIHYHQ-XHSDSOJGSA-N Phe-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N VIIRRNQMMIHYHQ-XHSDSOJGSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 1
- FYQSMXKJYTZYRP-DCAQKATOSA-N Pro-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FYQSMXKJYTZYRP-DCAQKATOSA-N 0.000 description 1
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- FFSLAIOXRMOFIZ-GJZGRUSLSA-N Pro-Gly-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)CNC(=O)[C@@H]1CCCN1 FFSLAIOXRMOFIZ-GJZGRUSLSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- FKYKZHOKDOPHSA-DCAQKATOSA-N Pro-Leu-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FKYKZHOKDOPHSA-DCAQKATOSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 1
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
- AIOWVDNPESPXRB-YTWAJWBKSA-N Pro-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2)O AIOWVDNPESPXRB-YTWAJWBKSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- BVRBCQBUNGAWFP-KKUMJFAQSA-N Pro-Tyr-Gln Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O BVRBCQBUNGAWFP-KKUMJFAQSA-N 0.000 description 1
- QDDJNKWPTJHROJ-UFYCRDLUSA-N Pro-Tyr-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 QDDJNKWPTJHROJ-UFYCRDLUSA-N 0.000 description 1
- JXVXYRZQIUPYSA-NHCYSSNCSA-N Pro-Val-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JXVXYRZQIUPYSA-NHCYSSNCSA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- MLSQXWSRHURDMF-GARJFASQSA-N Ser-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N)C(=O)O MLSQXWSRHURDMF-GARJFASQSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- XGQKSRGHEZNWIS-IHRRRGAJSA-N Ser-Pro-Tyr Chemical compound N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O XGQKSRGHEZNWIS-IHRRRGAJSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- FZNNGIHSIPKFRE-QEJZJMRPSA-N Ser-Trp-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZNNGIHSIPKFRE-QEJZJMRPSA-N 0.000 description 1
- HAUVENOGHPECML-BPUTZDHNSA-N Ser-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CO)=CNC2=C1 HAUVENOGHPECML-BPUTZDHNSA-N 0.000 description 1
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010051083 Therapy responder Diseases 0.000 description 1
- TWLMXDWFVNEFFK-FJXKBIBVSA-N Thr-Arg-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O TWLMXDWFVNEFFK-FJXKBIBVSA-N 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- MFMGPEKYBXFIRF-SUSMZKCASA-N Thr-Thr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFMGPEKYBXFIRF-SUSMZKCASA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 1
- XDGPTBVOSHKDFT-KKUMJFAQSA-N Tyr-Met-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O XDGPTBVOSHKDFT-KKUMJFAQSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 102100040012 UL16-binding protein 1 Human genes 0.000 description 1
- 101710173409 UL16-binding protein 1 Proteins 0.000 description 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 description 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- JFAWZADYPRMRCO-UBHSHLNASA-N Val-Ala-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JFAWZADYPRMRCO-UBHSHLNASA-N 0.000 description 1
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 1
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 1
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000276 dose-dependent cytotoxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical group C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 201000007574 granular cell carcinoma Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000044042 human KLRK1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000005211 struma ovarii Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The disclosure herein includes T cells genetically modified to express recombinant Chimeric Antigen Receptors (CARs) and recombinant chimeric co-stimulatory receptors (CCR), pharmaceutical compositions comprising the T cells, methods of making the T cells, and methods of treating cancer or tumors using the T cells. The CAR may comprise an extracellular domain comprising an extracellular domain of the NKG2D receptor, a transmembrane domain, and an intracellular signaling domain, and not a costimulatory signaling domain. The CCR may comprise an extracellular domain comprising a PD-L1 specific single-chain variable fragment, a transmembrane domain, a costimulatory signaling domain, and no intracellular signaling domain.
Description
Technical Field
The present invention relates generally to the fields of biotechnology and cell therapy. In particular, the present invention relates to genetically modified T cells for cancer immunotherapy, methods for their preparation and use in patients in need thereof.
Background
Adoptive transfer of T lymphocytes bearing Chimeric Antigen Receptors (CARs) is very effective in eliminating the substantial burden of certain types of hematological cancers and has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of B cell leukemia. The CAR constructs combine the specific and high affinity binding functions of B cell secreted monoclonal antibodies with the intracellular signaling domain of the T Cell Receptor (TCR) and the cytotoxic ability of T cells to redirect T cells to cancer cells and achieve efficient killing of target cells. Activation of T cells by CARs is independent of TCR interaction with Major Histocompatibility Complex (MHC) -peptide complex, overcoming immune evasion mechanisms often used by tumor cells, such as down-regulation of MHC class I molecules and the development of antigen processing defects.
The first generation CARs consisted of an extracellular tumor-specific domain (e.g., a single chain variable fragment (scFv) from a monoclonal antibody), a transmembrane domain, and an intracellular signaling moiety for T cell activation. Despite the tremendous efforts, the first generation of CAR-T cell studies did not reach the expected clinical outcome, mainly because CAR-T cells are poorly proliferated, resulting in short in vivo life span and insufficient tumor killing.
Complete activation of T cells requires two signals. The first signal is antigen-specific and is provided by a T Cell Receptor (TCR) that interacts with an antigenic peptide-MHC complex on the surface of an antigen presenting cell. The second signal is antigen-nonspecific, being transmitted by the interaction between costimulatory molecules expressed on antigen presenting cells and costimulatory receptors on T cells. One such example is the interaction of B7 ligand with the co-stimulatory receptor CD28; the interaction between 4-1BB ligand (CD 137L) and 4-1BB (CD 137) receptor is another example. The costimulatory signals promote the synthesis and secretion of cytokines produced by the antigen presenting cells and/or the activated T cells themselves. The second signal is crucial for proper T cell activation without anergy, and can promote long-term proliferation of activated T cells. In view of the important role of dual signaling on T cell activation, second generation CARs include intracellular co-stimulatory moieties, such as those from CD28 and 4-1BB receptors, and significantly improve the function of modified CAR-T cells, particularly the in vivo proliferation and persistence of CAR-T cells, making these CAR-T cells a "true live drug" in patients.
Although adoptive transfer of CAR-T cells constitutes a very promising therapeutic strategy for leukemia, the transformation of this approach for non-hematologic malignancies is challenging due to the specific pathophysiological characteristics of solid tumors. Major limitations of clinical CAR-T cell technology against solid tumors include factors affecting target antigen selection (e.g., tumor heterogeneity and antigen-loss variants), intrinsic negative regulatory mechanisms of the Tumor Microenvironment (TME) (e.g., PD-L1/PD-1 signaling pathways), and off-tumor (on-target) toxicity at the target.
The programmed cell death 1 (PD-1) receptor (CD 279) is an inhibitory immune receptor that plays an important role as an immune checkpoint, especially in T cell co-suppression and depletion. The interaction between PD-1 and its cognate ligand, PD-L1, is one of the major processes used by many tumors for immunosuppression and evasion. PD-1 is expressed on activated lymphocytes and has been shown to negatively modulate antigen receptor signaling upon binding to PD-L1 expressed on tumor cells, resulting in impaired immune cell effector functions such as cell proliferation, cytokine secretion and reduced tumor cell lysis. Using PD-L1 detection antibodies and immunohistochemical staining, high PD-L1 expression in tumor cells has been found to correlate with poor prognosis in terms of overall survival of various human cancers. Thus, PD-L1 expression has been introduced into clinical practice as a biomarker for selecting PD-1/PD-L1 antibody therapy responders. The use of monoclonal antibodies (mabs) to modulate PD-1/PD-L1 interactions is a method known as "immune checkpoint blockade" that has produced a good clinical response and improved overall survival in melanoma, renal cell carcinoma, non-small cell lung cancer and other tumor patients. However, PD-1mAb treatment may lead to immune-related adverse events (irAE), which may be serious or even fatal. The most serious adverse event of PD-1mAb treatment was pneumonia, which led to the death of 3 people in an early study.
The present invention addresses some of the above-mentioned shortcomings in the field of Chimeric Antigen Receptor (CAR) modified T lymphocytes for the treatment of cancer, in particular solid tumors.
Disclosure of Invention
In one aspect, the invention discloses a T cell genetically modified to express: i) A recombinant Chimeric Antigen Receptor (CAR) comprising (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of the NKG2D receptor; and ii) a recombinant Chimeric Costimulatory Receptor (CCR) comprising (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, (c) a costimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-L1 specific single-chain variable fragment (scFv).
In another aspect, the invention discloses a pharmaceutical composition comprising a pharmaceutically effective amount of the T cells of the invention, and a pharmaceutically acceptable excipient.
In another aspect, the invention features a method of making a T cell of the invention, the method comprising: a) Obtaining or providing a T cell; b) Providing i) a recombinant nucleic acid encoding a recombinant CAR; and ii) a recombinant nucleic acid encoding a CCR; and c) transferring the recombinant nucleic acid encoding the recombinant CAR and the recombinant nucleic acid encoding the CCR into a T cell.
In yet another aspect, the invention discloses a method of treating cancer or tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a T cell or pharmaceutical composition of the invention.
In a further aspect, the present invention discloses a method of treating a cancer or tumor in a subject in need thereof, the method comprising: a) Obtaining T cells from the subject or a donor different from the subject to be treated; b) Providing i) a recombinant nucleic acid encoding a recombinant Chimeric Antigen Receptor (CAR), wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of the NKG2D receptor; and ii) a recombinant nucleic acid encoding a recombinant Chimeric Costimulatory Receptor (CCR), wherein the recombinant CCR comprises (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) a costimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-1L1 specific single-chain variable fragment (scFv); c) Transferring a recombinant nucleic acid encoding a recombinant CAR and a recombinant nucleic acid encoding a recombinant CCR into a T cell to obtain a genetically modified T cell; and d) administering to the subject a pharmaceutically effective amount of the T cells obtained from c).
Drawings
The invention will be better understood with reference to the detailed description when considered in connection with non-limiting embodiments and the accompanying drawings, wherein:
figure 1 shows a schematic of the chimeric receptors described in the present application. Figure 1A shows that the first generation NKG2D CARs were generated by fusing the extracellular domain of the NKG2D receptor with an activation domain. The activation domain is derived from CD3 ζ or DAP12. FIG. 1B shows that α PD-L1 CCR was generated by fusion of a PD-L1 specific scFv to a single costimulatory signaling domain. Figure 1C shows that the PD-1 Chimeric Switch Receptor (CSR) is generated by fusing the extracellular domain of the PD-1 inhibitory receptor with a single costimulatory signaling domain. In FIGS. 1B and 1C, the co-stimulatory signaling domain is derived from 4-1BB or CD28. FIG. 1D shows that two NKG2D CAR-based combinations described in this application were generated by pairing a first generation NKG2D CAR with either alpha PD-L1 CCR (CAR-T1) or PD-1 CSR (CAR-T2). CAR, chimeric antigen receptor; CCR, chimeric costimulatory receptor; CSR, chimeric switch receptor.
FIG. 2 shows bar graph results of cytotoxicity assays, demonstrating that CAR-T1 and CAR-T2 modified T cells exhibit dose-dependent cytotoxicity against a panel of cancer cell lines. HepG2 (NKG 2DL +), cav 3 (NKG 2DL +, PD-L1 +) and Detroit-562 (NKG 2DL +, PD-L1+, PD-L2 +) cancer cells were used as target cells in a standard 2-hour Delfia time-resolved cytotoxicity assay. CAR-T1 and CAR-T2 modified T cells were seeded with target cells at different E: T ratios of 20 and 10. Both CAR-T1 and CAR-T2 show a dose-dependent increase in cytotoxicity against target cells. No significant difference was observed in cytotoxicity of CAR-T1 and CAR-T2 on all three cell lines (NS, p > 0.05). T, effector and target. Data shown are mean ± SD of triplicates, representative of three independent experiments. Statistical analysis was performed by two-way analysis of variance followed by Tukey's multiple comparisons.
Figure 3 antigen-dependent expansion of nkg2d CAR-T cells was further enhanced by α PD-L1 CCR. CAR-T1 and CAR-T2 cells were expanded with K562 myeloid leukemia cells expressing NKG2D ligand and PD-1 ligand. A batch of fresh gamma irradiated K562 feeder cells was used every 10 days with an E: T ratio of 2. Data shown are the number of cells obtained from trypan blue exclusion assay on days 17, 27, and 37 after electroporation of DNA from one donor, representing three independent experiments.
FIG. 4. Incorporation of α PD-L1 CCR enhances the development of CCR7-/CD45 RA-responsive memory T cells. The CAR-T1 and CAR-T2 groups were characterized for memory T development by detection of CCR7 and CD45RA antigens. (A) The proportion of CCR7-CD45RA + effector T cells in CAR-T1 and CAR-T2 in the middle and end stages of the expansion phase. (B) The proportion of CCR7-CD45 RA-effector memory cells in CAR-T1 and CAR-T2 in the middle and end stages of expansion. Data shown are single measurements from one donor, representative of three independent experiments.
Figure 5. Incorporation of α PD-L1 CCR attenuated T cell depletion marker expression. (a) single endpoint measurement from three donors: at the end of the amplification phase depicted in FIG. 3, expression levels of PD-1, TIGIT, TIM3, and LAG3 were assessed on CAR-T1 and CAR-T2 cells. (B) Summary mean of expression levels of each of the depletion markers classified according to CAR panel.
car-T cell therapy eliminated established tumors in the mouse xenograft model. Four groups of mice (5 mice per group) received 2X 10 6 Intraperitoneal injection of individual HCT116-Luc human colorectal cancer cells (day 0), followed by intraperitoneal injection of PBS, control CAR-T cells, T cells modified with NKG2D CAR + PD-1 CSR, or T cells modified with NKG2D CAR + α PD-L1 CCR on days 7 and 32 (1 × 10 injections per mouse per time) 7 Individual CAR-T cells). Growth of HCT116 was monitored by bioluminescence imaging on the indicated date. A bioluminescent image is displayed.
car-T cell treatment significantly prolonged survival of mice vaccinated with human cancer cells. In the mouse xenograft model described in fig. 6, animal survival was monitored up to 150 days after tumor inoculation and analyzed by Kaplan-Meier method.
Figure 8 shows a schematic of the design concept of constructs used to modify T cells as described in the present disclosure.
Definition of
"genetically modified cell" refers to any cell of any organism that is modified, transformed or manipulated by the addition or modification of a gene, DNA or RNA molecule, or protein or polypeptide.
A "T cell" is a lymphocyte that develops in the thymus and plays a central role in the immune response. T cells can be distinguished from other lymphocytes by the presence of T cell receptors on the cell surface. These immune cells originate from bone marrow-derived precursor cells, and once they migrate into the thymus, develop into several different types of T cells. T cells have been initially classified into a series of subpopulations according to their function, but have also been classified into subpopulations according to the expression pattern of the relevant gene or protein. The T Cell Receptor (TCR) is a molecule found on the surface of T cells, responsible for recognizing antigenic fragments as peptides bound to Major Histocompatibility Complex (MHC) molecules. The TCR consists of two distinct protein chains (i.e., it is a heterodimer). In humans, in most T cells, the TCR consists of an alpha chain and a beta chain (encoded by TRA and TRB, respectively), and is therefore referred to as an α β T cell. In a small fraction of T cells, the TCR consists of gamma and delta chains (encoded by TRG and TRD, respectively), and is therefore termed a gamma delta T cell. For different classes of T cells, the capacity to differentiate and proliferate increases in the following order: effector T cells, effector memory T cells, central memory T cells, stem cell memory T cells. Instead, their effector functions, such as cell-mediated cytotoxicity and cytokine release, decrease in the same order. The clinical efficacy of CAR-T cells is directly related to the ability to proliferate and persist in vivo. Thus, the higher memory order allows CAR-T cells to persist in the patient for a longer period of time, thereby exerting a more durable anti-tumor activity.
As used herein, the term "chimeric antigen receptor" or abbreviated form "CAR" refers to an artificial receptor protein or chimeric immune receptor and includes engineered receptors that specifically engraft the artificial onto specific immune effector cells. CARs can be used to provide T cells with the specificity of a monoclonal antibody, so that a large number of specific T cells can be generated, e.g., for adoptive cell therapy. The CAR typically comprises an intracellular activation domain, a transmembrane domain, and an extracellular domain comprising an antigen binding region. CARs can combine antibody-based specificity for a desired antigen with an intracellular domain that activates a T cell receptor to produce a chimeric protein with specific cellular immune activity (e.g., anti-tumor cellular immune activity). In some cases, molecules can be co-expressed with the CAR, including co-stimulatory molecules, reporter genes for imaging, gene products that conditionally clear NK cells upon addition of a prodrug, homing receptors, chemokines, chemokine receptors, cytokines, and cytokine receptors.
As used herein, the term "chimeric co-stimulatory receptor" or abbreviated form "CCR" refers to an artificial receptor protein or chimeric immunoreceptor that contributes to the complete activation of a particular immune effector cell, such as a T cell. For example, T cells require two signals to be fully activated, the first being an antigen-specific signal provided by the T Cell Receptor (TCR), and the second being an antigen-non-specific costimulatory signal provided by the interaction between the costimulatory molecule and the costimulatory receptor. The CCR typically comprises an extracellular domain containing an antigen binding region, a transmembrane domain, a costimulatory signaling domain, but does not comprise an intracellular activation domain. Thus, CCR alone does not result in complete activation and production of immune effector cells. CCR must generally be used with another recombinant receptor containing an intracellular activation domain (e.g., CAR) in order to fully activate immune effector cells.
As used herein, the term "antigen" is a molecule capable of being bound by an antibody or cell surface receptor. Antigens are commonly used to induce a humoral immune response and/or a cellular immune response leading to the production of lymphocytes.
Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD 274) or B7 homolog 1 (B7-H1), is a protein encoded by the CD274 gene in humans. PD-L1 is a 40kDa type 1 transmembrane protein which acts as a ligand for PD-1. Binding of PD-L1 to its receptor PD-1 on T cells delivers a signal that inhibits TCR-mediated activation of IL-2 production and T cell proliferation. Binding of PD-L1 to the inhibitory checkpoint molecule PD-1 delivers an inhibitory signal based on interaction with a phosphatase (SHP-1 or SHP-2) through an immunoreceptor tyrosine-based switching motif (ITSM). This reduces the proliferation of antigen-specific T cells in the lymph nodes, while reducing apoptosis of regulatory T cells (anti-inflammatory, suppressor T cells) -further mediated by lower regulation of the gene Bcl-2. Upregulation of PD-L1 may allow cancer to evade the host immune system.
Programmed cell death protein 1 in humans, also known as PD-1 and CD279 (cluster of differentiation 279), is encoded by the PDCD1 gene. PD-1 is a cell surface receptor belonging to the immunoglobulin superfamily, expressed on T cells and pre-B cells. PD-1 binds two ligands, PD-L1 and PD-L2.PD-1 regulates the immune system's response to human cells by down-regulating the immune system and promotes self-tolerance by inhibiting T cell inflammatory activity. PD-1 is an immune checkpoint that prevents autoimmunity by two mechanisms. First, it promotes apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes. Second, it reduces apoptosis of regulatory T cells (anti-inflammatory, suppressor T cells). Exemplary sequences of the extracellular domain of PD-1 are (from N-terminus to C-terminus): <xnotran> PGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLV (SEQ ID NO: 1), : </xnotran> <xnotran> CCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTG (SEQ ID NO: 2). </xnotran>
As used herein, the term "single chain variable fragment" or "scFv" refers to the variable region of the heavy chain (V) of an immunoglobulin H ) And light chain variable region (V) L ) The fusion protein of (3), linked by a short linker peptide of 10 to about 25 amino acids. The linker is generally glycine rich for increased flexibility and serine or threonine rich for increased solubility, and V may be substituted H N-terminal of (1) and V L Are linked and vice versa. Despite the removal of the constant region and the introduction of the linker, the protein retains the specificity of the original immunoglobulin.
The terms "polynucleotide", "nucleic acid" and "oligonucleotide" are used interchangeably to refer to a polymeric form of nucleotides of any length, which may be deoxyribonucleotides or ribonucleotides or analogs thereof. The polynucleotide may have any three-dimensional structure and may perform any known or unknown function. The following are non-limiting examples of polynucleotides: a gene or gene fragment (e.g., a probe, primer, EST, or SAGE tag), an exon, an intron, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozyme, cDNA, recombinant polynucleotide, branched polynucleotide, plasmid, vector, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probe, and primer. Polynucleotides may include modified nucleotides, such as methylated nucleotides and nucleotide analogs. Modifications to the nucleotide structure, if present, may be made before or after polynucleotide assembly. The nucleotide sequence may be interrupted by non-nucleotide components. The polynucleotide may be further modified after polymerization, for example by conjugation with a labeling component. The term also refers to double-stranded and single-stranded molecules. Unless otherwise specified or required, a polynucleotide includes both the double-stranded form and each of the two complementary single-stranded forms known or expected to constitute the double-stranded form.
As used herein, the term "recombinant nucleic acid" refers to a nucleic acid formed by the laboratory process of genetic recombination (e.g., molecular cloning) to bring together genetic material from multiple sources. The nucleic acid sequence used to construct the recombinant nucleic acid molecule may be derived from any species. For example, human nucleic acids can bind to bacterial nucleic acids. In addition, nucleic acid sequences not found in nature can be produced by chemical synthesis of nucleic acids and incorporated into recombinant molecules. Proteins that can be produced by the expression of recombinant nucleic acids in living cells are referred to as recombinant proteins. When a recombinant nucleic acid encoding a protein is introduced into a host organism, it is not necessary to produce the recombinant protein. Expression of foreign proteins requires the use of specialized expression vectors and often requires significant recombination by foreign coding sequences.
As used herein, the term "vector" refers to an extrachromosomal nucleic acid comprising an intact replicon, such that the vector can be replicated when placed (e.g., by a transformation process) within a permissive cell. A vector can replicate in one cell type (e.g., bacteria), but has a limited ability to replicate in another cell (e.g., mammalian cell). The vector may be viral or non-viral. Exemplary non-viral vectors for delivering nucleic acids include naked DNA; DNA complexed with cationic lipids, alone or in combination with cationic polymers; anionic and cationic liposomes; DNA-protein complexes and particles comprising DNA condensed with cationic polymers (such as heterogeneous polylysines, fixed length oligopeptides, and polyethylene imines), in some cases in liposomes; and the use of ternary complexes comprising virus and polylysine-DNA.
As used herein, the term "transfer" or "transfection" refers to the general process of introducing an exogenous nucleic acid into a host cell, which may be mechanical transfection (including electroporation), chemical transfection or viral transduction. A "transfected" cell is a cell that has been transfected with exogenous nucleic acid using any of the methods described above. Cells include primary subject cells and their progeny.
As used herein, the term "autologous" means any material derived from the same individual that is subsequently reintroduced into the individual.
As used herein, the term "allogenic" refers to any material derived from an individual that is different from the individual into which it is subsequently introduced.
As used herein, "percent identity" refers to sequence identity between two peptides or between two nucleic acid molecules. Percent identity can be determined by comparing the position in each sequence, and the sequences can be aligned for comparison purposes (align). When a position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position.
As used herein, the terms "peptide," "polypeptide," and "protein" are used interchangeably to refer to a compound having amino acid residues covalently linked by peptide bonds. The protein or peptide must comprise at least two amino acids, and there is no limit to the maximum number of amino acids that can comprise the protein or peptide sequence. Polypeptides include any peptide or protein having two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains (also commonly referred to in the art as, for example, peptides, oligopeptides, and oligomers) and longer chains (commonly referred to in the art as proteins), each of many types. "polypeptide" includes, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, and the like. The polypeptide includes a natural peptide, a recombinant peptide, a synthetic peptide, or a combination thereof.
As used herein, the phrase "homologous" or "variant" nucleotide sequence, or "homologous" or "variant" amino acid sequence, refers to a sequence characterized by at least a specified percentage of identity at the nucleotide or amino acid level. Homologous nucleotide sequences include those sequences that encode naturally occurring allelic variants and mutations of the nucleotide sequences described herein. Homologous nucleotide sequences include nucleotide sequences encoding proteins of mammalian species other than humans. Homologous amino acid sequences include those amino acid sequences that contain conservative amino acid substitutions and the polypeptides have the same binding and/or activity. In some examples, a homologous nucleotide or amino acid sequence has at least 60% or more (e.g., at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98% or at least 99%) identity to a comparative sequence. In some examples, a homologous nucleotide or amino acid sequence is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a comparative sequence. In some examples, a homologous amino acid sequence has no more than 15, or no more than 10, or no more than 5, or no more than 3 conservative amino acid substitutions. Percent identity can be determined using default settings, for example, by the Gap program (Wisconsin sequence analysis software package, UNIX version 8, genetics Computer group, university Research park, madison Wis.) using the algorithms of Smith and Waterman. In some examples, recombinant nucleic acid molecules for modifying T cells according to the present disclosure are homologous to exemplary nucleotide sequences disclosed herein (e.g., sequences provided in any of SEQ ID NOs: 24, 26, 28, and 30). In some other examples, the Chimeric Antigen Receptor (CAR) and/or chimeric co-stimulatory receptor (CCR) expressed in the modified T cell is homologous to an exemplary amino acid sequence disclosed herein (e.g., a sequence provided in any of SEQ ID NOs: 23, 25, 27, and 29).
The term "expression" refers to the production of a gene product in a cell.
The term "transient" when referring to expression means that the polynucleotide is not incorporated into the genome of the cell. Conversely, when referring to expression, the term "stable" means that the polynucleotide is incorporated into the genome of the cell. Transient expression may occur from an introduced construct that contains expression signals that are functional in the host cell, but that does not replicate and integrate little into the host cell, or that does not proliferate. Transient expression can also be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest, although such inducible systems often exhibit low basal expression levels. Stable expression can be achieved by introducing a nucleic acid construct that can be integrated into the host genome or autonomously replicated in the host cell. Stable expression of a gene of interest can be selected by using a selectable marker located on or transfected with the expression construct, and then by selecting cells that express the marker. Where stable expression results from integration, integration of the construct may occur randomly within the host genome, or may be targeted by use of such constructs: the construct contains a region of homology to the host genome sufficient to target recombination with the host locus. When the construct is targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions may be provided by the endogenous locus. To achieve expression in a host cell, the transformed nucleic acid is operably associated with transcriptional and translational initiation and termination regulatory regions that function in the host cell.
As used herein, the term "tumor" refers to a lump in a part of the body caused by abnormal growth of tissue, usually without inflammation. Tumors can be benign or malignant (i.e., cancerous). Benign tumors do not infiltrate nearby tissue or spread to other parts of the body. Common types of benign tumors include adenomas, fibroids, hemangiomas, lipomas, meningiomas, myomas, neuromas and osteochondromas. Adenomas are benign tumors of epithelial tissue that begin in glandular or adenoid structures. A common type of adenoma is colonic polyps. Adenomas may also grow in the liver or in the adrenal gland, pituitary gland or thyroid gland. Fibroids are tumors of fibrous or connective tissue that can grow in any organ. Hemangiomas are accumulations of vascular cells in the skin or internal organs. Lipomas arise from the growth of adipocytes. They are the most common benign tumors in adults, often found in the neck, shoulders, back or arms. Meningiomas are tumors that develop from membranes surrounding the brain and spinal cord. Myomas are tumors that grow from muscle. Neuroma is a tumor that develops from a nerve. Osteochondrosis is a tumor that develops from bone.
As used herein, the term "cancer" refers to uncontrolled cellular proliferation due to loss of normal control, resulting in uncontrolled growth, lack of differentiation, local tissue infiltration, and often metastasis. There are several major types of cancer. Cancer is cancer that begins in the skin or tissues lining or covering internal organs. Sarcomas are cancers that begin in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a cancer that begins in hematopoietic tissues such as bone marrow, resulting in the production and entry of large numbers of abnormal blood cells into the blood. Lymphomas and multiple myeloma are cancers that begin with cells of the immune system. Central nervous system cancer is a cancer of tissues that begin in the brain and spinal cord.
Detailed Description
The inventors of the present application found that after genetic modification of T cells to express a recombinant CAR comprising the extracellular domain of the NKG2D receptor and a recombinant CCR specifically targeting PD-Ll, the genetically modified T cells facilitate more precise cancer targeting by exhibiting specificity for cancer cells expressing both PD-L1 and NKG2D ligands, thereby minimizing the risk of on-target tumor removal associated with CAR-T cell therapy. The inventors have also found that such genetically modified T cells can evade major immunosuppressive mechanisms within the Tumor Microenvironment (TME).
Thus, in one example, the invention relates to a T cell genetically modified to express: i) A recombinant Chimeric Antigen Receptor (CAR) comprising (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of the NKG2D receptor; and ii) a recombinant Chimeric Costimulatory Receptor (CCR) comprising (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, (c) a costimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-L1 specific single-chain variable fragment (scFv).
In some examples, the extracellular domain of the recombinant CAR is the extracellular domain of the NKG2D receptor. In one example, the extracellular domain of the NKG2D receptor has the following amino acid sequence (from N-terminus to C-terminus): FNQEVPLTESYCGPCPKNWICYKNNCYQFDFDESKNWYESQASCMSQNASSKLVYSKEDQDLLKLVGS YHWMGLVHIPTGQWQWGSILNLLTIIEMQKGDCALYASSFKGYIIENCSTPNTYICQRRAS (SEQ ID NO: 3) encoded by the following exemplary nucleotide sequences: <xnotran> TTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAATACGTACATCTGTATGCAAAGGACTGTGGCTAGC (SEQ ID NO: 4). </xnotran> NKG2D ligands are structural homologues of MHC class I molecules. NKG2D ligands are absent or poorly expressed in normal tissues, but are widely expressed in various malignant and virally infected tissues. Examples of human NKG2D ligands include class I chain-associated molecules a and B (MICA and MICB) proteins and retinoic acid early transcript-1 (RAET 1), also known as UL-16 binding protein. Examples of mouse NKG2D ligands include five different RAET1 subtypes (RAET 1 α, RAET1 β, RAET1 γ, RAET1 δ, and RAET1 ∈), three different H60 subtypes (H60 a, b, and c), and UL16 binding protein 1 (encoded by the MULT1 gene). Although NKG2D ligands are structural homologues of MHC class I molecules, they do not present antigen to T cells or bind β 2-microglobulin. In some examples, the NKG2D ligand to which the extracellular domain of the chimeric antigen receptor binds is a membrane-bound ligand.
In some examples, the extracellular domain of the recombinant CCR is a PD-L1 specific scFv, referred to as an α PD-L1 scFv. In a specific example, the PD-L1 scFv has the following amino acid sequence (from N-terminus to C-terminus): <xnotran> QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYGFSWVRQAPGQGLEWMGWITAYNGNTNYAQKLQGRVTMTTDTSTSTVYMELRSLRSDDTAVYYCARDYFYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIKAS (SEQ ID NO: 5), : </xnotran> <xnotran> CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCGACTATGGTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCACCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGTCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGGTCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGTCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAGCTAGC (SEQ ID NO: 6). </xnotran> In a specific example, the heavy chain variable domain of the PD-L1 scFv has the followingAmino acid sequence (from N-terminus to C-terminus): QVQLVQSGAEVKKPGASVKSGYTFTDYGVFVRQACPGQGLEW WITAYNYNTTNYAQKLQGRVTMTTSTSTSTVYMRSLRSDAVYYCARDYFYGMDVWGQGTTVSS (SEQ ID NO: 7), consisting of the following exemplary nucleotide coding sequences: <xnotran> CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCGACTATGGTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCACCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGTCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA (SEQ ID NO: 8). </xnotran> In a particular example, the light chain variable domain of the PD-L1 scFv has the following amino acid sequence (from N-terminus to C-terminus): <xnotran> EIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK (SEQ ID NO: 9), : </xnotran> <xnotran> GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGTCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO: 10). </xnotran> The heavy chain variable domain and the light chain variable domain of the PD-L1 scFv may be linked by a linker peptide. In a specific example, the heavy chain variable domain and the light chain variable domain of the PD-L1 scFv are encoded by a sequence of amino acids (from N-terminus to C-terminus) (G4S) 3 Linker peptide ligation: GGGGSGGGGSGGGGS (SEQ ID NO: 11), encoded by the following exemplary nucleotide sequence: GGTGGAGGGCGGTTCAGGCGGAGGGTGGCAGCGGCGGTGGCGGGTCG (SEQ ID NO: 12).
The extracellular domain of the recombinant Chimeric Antigen Receptor (CAR) and/or the recombinant Chimeric Costimulatory Receptor (CCR) may also comprise a hinge region. A hinge region is a sequence located, for example, between an antigen binding region and a transmembrane domain. The sequence of the hinge region may be obtained from any suitable sequence, for example from any species, including human or parts thereof. In some examples, the hinge region comprises a hinge region of a human protein comprising CD3, CD-8 α, CD28, 4-1BB, OX-40, a T cell receptor α or β chain, a CD3zeta chain, CD28, CD3 ε, CD45, CD4, CD5, CD8a, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, CD154, functional derivatives thereof, and combinations thereof. In some embodiments, the hinge region is a hinge region of CD3, CD8, or CD28. In some examples, the hinge region of the recombinant CAR and the hinge region of the recombinant CCR are the same. In some other examples, the hinge region of the recombinant CAR and the hinge region of the recombinant CCR are different. In some examples, the hinge region may be one selected from, but not limited to, an immunoglobulin (e.g., igG1, igG2, igG3, igG4, and IgD).
It will be appreciated that the antigen binding region may include some variability within its sequence and still be selective for the targets disclosed herein. Thus, it is contemplated that the polypeptides of the antigen binding region may be at least 95%, at least 90%, at least 80%, or at least 70% identical to the antigen binding region polypeptide sequences disclosed herein and still be selective for the targets disclosed herein and are within the scope of the present disclosure.
The transmembrane domain of the recombinant CAR and/or recombinant CCR includes a hydrophobic polypeptide that spans the cell membrane. In particular, the transmembrane domain spans from one side of the cell membrane (extracellular) to the other side of the cell membrane (intracellular or cytoplasmic).
In some examples, the transmembrane domain is artificially designed such that more than 25%, more than 50%, or more than 75% of the amino acid residues of the domain are hydrophobic residues, such as leucine and valine.
The transmembrane domain may be in the form of an alpha helix or a beta barrel, or a combination thereof. The transmembrane domain may comprise a polytypic (polytopic) protein having a number of transmembrane segments, each a-helix, a β -sheet, or a combination thereof.
In one example, a transmembrane domain that is naturally associated with one of the domains in the CAR or CCR is used. In another example, the transmembrane domains are selected or modified by amino acid substitutions to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins, thereby minimizing interaction with other members of the receptor complex.
For example, transmembrane domains include transmembrane domains of T cell receptor alpha or beta chains, CD3zeta chains, CD3 epsilon, CD8, CD45, CD4, CD5, CD7, CD9, CD16, CD22, CD28, CD33, CD37, CD64, CD80, CD86, CD68, CD134, CD137, ICOS, CD41, CD154, functional derivatives thereof, and combinations thereof. In some examples, the transmembrane domain of the recombinant CAR and the transmembrane domain of the recombinant CCR are the same. In some other examples, the transmembrane domain of the recombinant CAR and the transmembrane domain of the recombinant CCR are different. In a specific example, the transmembrane domain of the recombinant CAR is a CD28 transmembrane domain. In a specific example, the transmembrane domain of the recombinant CAR has the following amino acid sequence (from N-terminus to C-terminus): ESKYGPPCPPCPFWVLVVGGVLLACYSLLVTVAFIIFWV (SEQ ID NO: 13), encoded by the following exemplary nucleotide sequence: <xnotran> GAATCTAAATATGGCCCCCCTTGCCCACCATGTCCCTTCTGGGTTTTGGTAGTTGTCGGCGGGGTGCTTGCTTGCTATTCATTGTTGGTTACGGTGGCTTTTATAATTTTCTGGGTA (SEQ ID NO: 14). </xnotran> In a specific example, the transmembrane domain of the recombinant CCR is a CD8 transmembrane domain. In one particular example, the transmembrane domain of the recombinant CCR has the following amino acid sequence (from N-terminus to C-terminus): <xnotran> FVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN (SEQ ID NO: 15), : </xnotran> <xnotran> TTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAAC (SEQ ID NO: 16). </xnotran>
The intracellular signaling domain of the recombinant CAR is responsible for activating at least one of the normal effector functions of the immune cell into which the recombinant CAR has been placed. The term "effector function" refers to a specialized function of a differentiated cell, such as a T cell. The intracellular signaling domain typically includes at least one domain comprising an immunoreceptor tyrosine-based activation motif (ITAM). Each ITAM has two repeats of the consensus sequence Tyr-X-X-Leu/Ile (X is any amino acid) 6 to 8 amino acids apart. Tyrosine residues in ITAMs are phosphorylated upon interaction of the receptor molecule with its ligand and form docking sites for other proteins involved in the cell signaling pathway. In some examples, the intracellular signaling domain of the recombinant CAR comprises only one ITAM, or no more than one ITAM. In some examples, a T cell genetically modified to express a recombinant CAR comprising only one ITAM in the intracellular signaling domain releases a lower level of a cytokine as compared to a T cell expressing a recombinant CAR comprising more than one ITAM in the intracellular signaling domain. In some examples, the intracellular signaling domain in the CAR comprises part or all of CD3 ζ, or a DAP molecule such as DAP12, or a combination thereof. In a specific example, the intracellular signaling domain used is CD3 ζ. In one particular example, the intracellular signaling domain used is DAP12. In a specific example, the intracellular signaling domain of the CAR has the following amino acid sequence (from N-terminus to C-terminus): YFLRLVPRGGAAAATRKQRTETTESPTYQELQGQRQRSVYSDLNTQRPYK (SEQ ID NO: 17), encoded by the following exemplary nucleotide sequence: <xnotran> TACTTCCTGGGACGACTTGTTCCTCGGGGGCGGGGTGCTGCAGAAGCTGCAACGCGAAAACAAAGAATTACCGAGACTGAGAGTCCGTATCAAGAACTGCAGGGCCAAAGAAGCGACGTTTACTCCGATCTCAATACCCAACGGCCTTACTACAAA (SEQ ID NO: 18). </xnotran>
In some examples, the recombinant CARs disclosed herein do not comprise a costimulatory signaling domain, e.g., OX40; CD27; CD28; CD30; CD40; PD-1; CD2; CD7; CD258; natural killer group 2 member C (NKG 2C); natural killer group 2 member D (NKG 2D), B7-H3; a ligand that binds at least one of CD83, ICAM-1, LFA-1 (CD 11a/CD 18), ICOS and 4-1BB (CD 137); CDS; ICAM-1; LFA-1 (CD 1a/CD 18); CD40; CD27; CD7; B7-H3; NKG2C; PD-1; ICOS; an active fragment thereof; a functional derivative thereof; and combinations thereof.
In some examples, a spacer domain is incorporated between the extracellular domain and the transmembrane domain of the recombinant CAR and/or recombinant CCR, or between the intracellular signaling domain and the transmembrane domain of the recombinant CAR. As used herein, the term "spacer domain" generally refers to any oligopeptide or polypeptide that functions to connect a transmembrane domain to an extracellular domain or an intracellular domain in a polypeptide chain. The spacer domain may comprise up to about 300 amino acids, or about 10 to about 100 amino acids, or about 25 to about 50 amino acids.
In a specific example, a recombinant CAR desired in a genetically modified T cell comprises an NKG2D receptor, a CD28 transmembrane domain, and a DAP12 intracellular signaling domain. In a specific example, a desired recombinant CCR in a genetically modified T cell comprises an alpha PD-L1 scFv, a CD8 transmembrane domain, and a 4-1BB costimulatory signaling domain.
The terms "CD3zeta", "CD3z" are used interchangeably herein to refer to the same T cell surface glycoprotein CD3zeta chain.
The costimulatory signaling domain of the recombinant CCR can enhance T cell proliferation, survival, and/or development. Examples of co-stimulatory signaling domains include, but are not limited to: 4-1BB, CD27, CD28, OX-40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, functional derivatives thereof, and combinations thereof. In a specific example, the co-stimulatory signaling domain is 4-1BB.4-1BB, also known as CD137, is a member of the Tumor Necrosis Factor (TNF) receptor family. In one particular example, the co-stimulatory signaling domain of the CCR has the following amino acid sequence (from N-terminus to C-terminus): RFSVVKRRKKLLYFKQPFMRPVQTTQEEDGCSCRAFEEEGGCEL (SEQ ID NO: 19), encoded by the following exemplary nucleotide sequence: <xnotran> CGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAGCTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG (SEQ ID NO: 20). </xnotran> In another specific example, the co-stimulatory signaling domain is CD28.
In some examples, to generate a recombinant CAR and/or recombinant CCR, a signal peptide is added to the 5' end of the recombinant CAR/CCR construct. In one particular example, the signal peptide is a GM-CSF signal peptide having the following sequence (from N-terminus to C-terminus): MLLLVTSLLLCELPHAPFLLIPGHAS (SEQ ID NO: 21), encoded by the following exemplary nucleotide sequence: ATGCTTCTCCTGGGGACAAGCCTTCTGTGAGTTACCACCCAGCATGCC (SEQ ID NO: 22).
In one example, the recombinant CAR without signal peptide has the following sequence (from N-terminus to C-terminus): <xnotran> FNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVASNWSHPQFEKGGGGSGGGGSNWSHPQFEKGGGGSGGGGSNWSHPQFEKGGGGSGGGGSESKYGPPCPPCPFWVLVVVGGVLACYSLLVTVAFIIFWVYFLGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSDVYSDLNTQRPYYK (SEQ ID NO: 23), : </xnotran> <xnotran> TTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAATACGTACATCTGTATGCAAAGGACTGTGGCTAGCAACTGGTCACACCCCCAGTTTGAGAAAGGTGGGGGAGGGTCAGGTGGTGGGGGGTCAAATTGGTCTCATCCCCAGTTCGAGAAGGGCGGAGGAGGTTCAGGTGGGGGTGGGAGCAACTGGAGCCACCCTCAATTTGAAAAAGGAGGTGGAGGGAGTGGAGGTGGTGGATCTGAATCTAAATATGGCCCCCCTTGCCCACCATGTCCCTTCTGGGTTTTGGTAGTTGTCGGCGGGGTGCTTGCTTGCTATTCATTGTTGGTTACGGTGGCTTTTATAATTTTCTGGGTATACTTCCTGGGACGACTTGTTCCTCGGGGGCGGGGTGCTGCAGAAGCTGCAACGCGAAAACAAAGAATTACCGAGACTGAGAGTCCGTATCAAGAACTGCAGGGCCAAAGAAGCGACGTTTACTCCGATCTCAATACCCAACGGCCTTACTACAAA (SEQ ID NO: 24). </xnotran> In one example, the recombinant CAR with signal peptide has the following sequence (from N-terminus to C-terminus): <xnotran> MLLLVTSLLLCELPHPAFLLIPGAHAFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVASNWSHPQFEKGGGGSGGGGSNWSHPQFEKGGGGSGGGGSNWSHPQFEKGGGGSGGGGSESKYGPPCPPCPFWVLVVVGGVLACYSLLVTVAFIIFWVYFLGRLVPRGRGAAEAATRKQRITETESPYQELQGQRSDVYSDLNTQRPYYK (SEQ ID NO: 25), : </xnotran> <xnotran> ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGGCGCGCATGCCTTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAATACGTACATCTGTATGCAAAGGACTGTGGCTAGCAACTGGTCACACCCCCAGTTTGAGAAAGGTGGGGGAGGGTCAGGTGGTGGGGGGTCAAATTGGTCTCATCCCCAGTTCGAGAAGGGCGGAGGAGGTTCAGGTGGGGGTGGGAGCAACTGGAGCCACCCTCAATTTGAAAAAGGAGGTGGAGGGAGTGGAGGTGGTGGATCTGAATCTAAATATGGCCCCCCTTGCCCACCATGTCCCTTCTGGGTTTTGGTAGTTGTCGGCGGGGTGCTTGCTTGCTATTCATTGTTGGTTACGGTGGCTTTTATAATTTTCTGGGTATACTTCCTGGGACGACTTGTTCCTCGGGGGCGGGGTGCTGCAGAAGCTGCAACGCGAAAACAAAGAATTACCGAGACTGAGAGTCCGTATCAAGAACTGCAGGGCCAAAGAAGCGACGTTTACTCCGATCTCAATACCCAACGGCCTTACTACAAA (SEQ ID NO: 26). </xnotran>
In one example, the recombinant CCR without signal peptide has the following sequence (from N-terminus to C-terminus): <xnotran> QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYGFSWVRQAPGQGLEWMGWITAYNGNTNYAQKLQGRVTMTTDTSTSTVYMELRSLRSDDTAVYYCARDYFYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIKASFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 27), : </xnotran> <xnotran> CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCGACTATGGTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCACCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGTCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGGTCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGTCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAGCTAGCTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACCGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAGCTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG (SEQ ID NO: 28). </xnotran> In one example, a recombinant CCR with a signal peptide has the following sequence (from N-terminus to C-terminus): <xnotran> MLLLVTSLLLCELPHPAFLLIPGAHAQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYGFSWVRQAPGQGLEWMGWITAYNGNTNYAQKLQGRVTMTTDTSTSTVYMELRSLRSDDTAVYYCARDYFYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIKASFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO: 29), : </xnotran> <xnotran> ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGGCGCGCATGCCCAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCGACTATGGTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCACCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGTCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCGGTGGCGGGTCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGTCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAGCTAGCTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACCGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAGCTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG (SEQ ID NO: 30). </xnotran>
In some examples, to measure the surface expression level of the recombinant CAR, a peptide tag is added to the recombinant CAR construct. In one example, a peptide tag is added between the extracellular domain and the transmembrane domain. In one particular example, the peptide tag is an ST2 tag, having the sequence (from N-terminus to C-terminus): NWSHPQFEEKGGGGGGSGGGGSNWSHPQFEEKGGGGGGSGGGGS (SEQ ID NO: 31), encoded by the following exemplary nucleotide sequence: <xnotran> AACTGGTCACACCCCCAGTTTGAGAAAGGTGGGGGAGGGTCAGGTGGTGGGGGGTCAAATTGGTCTCATCCCCAGTTCGAGAAGGGCGGAGGAGGTTCAGGTGGGGGTGGGAGCAACTGGAGCCACCCTCAATTTGAAAAAGGAGGTGGAGGGAGTGGAGGTGGTGGATCT (SEQ ID NO: 32). </xnotran>
Expression of the recombinant CAR and/or recombinant CCR in a genetically modified T cell can be transient or stable. In some examples, the constructs in each of fig. 1A and 1B are transiently or stably expressed in the genetically modified T cell.
In some examples, the genetically modified T cells disclosed herein target cancer or tumor cells that express both NKG2D ligands and PD-Ll. Binding of the NKG2D ligand to the extracellular domain of the recombinant CAR activates the genetically modified T cells, which then continue to proliferate, synthesize, and secrete cytokines. Binding of PD-L1 expressed on tumor cells to the extracellular domain of recombinant CCR activates the costimulatory signaling domain of recombinant CCR, thereby enhancing proliferation, survival and/or development of T cells and promoting cytokine synthesis and secretion. Upon binding to both PD-L1 and NKG2D ligands expressed by target tumor cells, the genetically modified T cells are fully activated and function.
The genetically modified T cells described herein can be provided as a composition or pharmaceutical composition. Thus, in one example, there is provided a pharmaceutical composition comprising a pharmaceutically effective amount of T cells as disclosed herein and a pharmaceutically acceptable excipient. The compositions described herein may be administered in a variety of ways depending on whether local or systemic treatment is desired. Administration can be topical, pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal) or systemic (e.g., oral) and/or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial (e.g., intrathecal or intraventricular) administration. In some examples, the route of administration may be selected from the group consisting of systemic administration, oral administration, intravenous administration, and parenteral administration.
The compositions or pharmaceutical compositions described herein may be provided in unit dosage form, wherein each dosage unit (e.g., injection) contains a predetermined amount of T cells as disclosed herein, alone or in appropriate combination with other active agents. The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of T cells as disclosed herein, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier or excipient, as appropriate. The specification for a unit dosage form depends on the particular pharmacodynamics associated with the pharmaceutical composition in a particular subject. The unit dosage forms may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredient with a pharmaceutical carrier or excipient. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid or semi-liquid carriers.
The compositions described herein may additionally comprise other auxiliary components commonly found in pharmaceutical compositions. Thus, for example, the compositions may contain additional, compatible, pharmaceutically active agents, such as antipruritics, astringents, local anesthetics, or anti-inflammatory agents, or may contain additional agents used to physically formulate various dosage forms of the compositions of the present invention, such as buffers, dyes, preservatives, antioxidants, opacifiers, thickeners, and stabilizers, or combinations thereof, which are suitable for use with pharmacologically active agents that may be added to the solution in any concentration suitable for use in eye drops. However, these materials, when added, should not unduly interfere with the biological activity of the components of the disclosed compositions. The formulations can be sterilized and, if desired, mixed with adjuvants, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants, flavors and/or aromatic substances and the like, which do not deleteriously interact with the T cells of the formulation.
In another example, there is provided a method of making a T cell genetically modified to express a recombinant CAR and a recombinant CCR as disclosed herein, the method comprising: a) Obtaining or providing a T cell; b) Providing i) a recombinant nucleic acid encoding a recombinant CAR; and ii) a recombinant nucleic acid encoding a CCR; and c) transferring the recombinant nucleic acid encoding the recombinant CAR and the recombinant nucleic acid encoding the CCR into a T cell. In some examples, the method further comprises, after step a), culturing the T cells to expand the number of T cells. T cell expansion methods known in the art may be used. In some examples, the recombinant nucleic acid encoding the recombinant CAR and the recombinant nucleic acid encoding the recombinant CCR are transferred into a T cell simultaneously. In some examples, the recombinant nucleic acid encoding the recombinant CAR and the recombinant nucleic acid encoding the recombinant CCR are transferred into T cells simultaneously, and the recombinant nucleic acids encoding the recombinant CAR and the recombinant CCR are cloned into the same vector. In some other examples, the recombinant nucleic acid encoding the recombinant CAR and the recombinant nucleic acid encoding the recombinant CCR are transferred into T cells sequentially.
Recombinant nucleic acids encoding recombinant CARs and/or recombinant CCR can be generated using methods known in the art. For the amino acid sequence of each domain, the base sequence encoding the amino acid sequence can be obtained from NCBI RefSeq ID or GenBenk accession number, and standard molecular biological and/or chemical procedures can be used to prepare nucleic acids as disclosed herein. For example, based on the base sequence, a polynucleotide may be synthesized, and a polynucleotide of the present disclosure may be prepared by combining DNA fragments obtained from a cDNA library using Polymerase Chain Reaction (PCR). The sequence of the open reading frame encoding the CAR and/or CCR can be obtained from a genomic DNA source, a cDNA source, or can be synthesized (e.g., by PCR), or a combination thereof. Depending on the size of the genomic DNA and the number of introns, it may be desirable to use cDNA or a combination thereof, as introns have been found to stabilize mRNA. In addition, it may be advantageous to use endogenous or exogenous non-coding regions to stabilize the mRNA.
The nucleotide sequence encoding the recombinant CAR and/or recombinant CCR can be inserted into an appropriate expression vector, i.e., a vector that contains the elements necessary for transcription and translation of the inserted protein coding sequence. A variety of host-vector systems are available for expression of protein coding sequences. These include, but are not limited to, mammalian cell systems infected with a virus (e.g., vaccinia virus, adenovirus, etc.), insect cell systems infected with a virus (e.g., baculovirus), microorganisms such as yeast containing yeast vectors, or bacteria transformed with phage, DNA, plasmid DNA, or cosmid DNA, transgenic plants, or transgenic non-human animals. The expression elements of the vectors vary in strength and specificity. Any of a variety of suitable transcription and translation elements may be used, depending on the host-vector system used.
Any known method for inserting a DNA fragment into a vector can be used to construct an expression vector containing a chimeric nucleotide sequence consisting of appropriate transcription/translation control signals and a protein coding sequence. Exemplary methods include in vitro recombinant DNA and synthetic techniques. Expression of the recombinant nucleic acid sequence encoding the recombinant CAR and/or the recombinant CCR can be regulated by the second nucleic acid sequence such that the recombinant CAR and/or the recombinant CCR is expressed in a host transformed with the recombinant DNA molecule. For example, expression of the recombinant CAR and/or recombinant CCR can be controlled by any promoter/enhancer element known in the art.
In some examples, the basic backbone of the recombinant expression vector is a commercially available vector into which each of the above elements is inserted. Exemplary expression vectors include, but are not limited to, pFastbac1, pALTER-Ex2, pCal-n-EK, pCal-c, pCal-Kc, pcDNA2.1, pDUAL, pET-3a-c, pET-9a-d, pET-11a-d, pET-12a-c, pET-14b, pET-15b, pET-16b, pET-17b, pET-19b, pET-20b (+), pET-21a-d (+), pET-22b (+), pET-23a-d (+), pET-24a-d (+), pET-25b (+), pET-26b (+), pET-21a (+), and pET-27b (+), pET-28a-c (+), pET-29a-c (+), pET-30a-c (+), pET-31b (+), pET-32a-c (+), pET-33b (+), pET-34b (+), pET-35b (+), pET-36b (+), pET-37b (+), pET-38b (+), pET-39b (+), pET-40b (+), pET-41a-c (+), pET-42a-c (+), pET-43a-c (+), TBpET-1, TBpElue-2, TBpElue-3, pGEMEX-1, pGEMEX-2, pRSET-3, pET-43a-c (+), pET-42 a-36 b (+), and TBpET-37 b (+) pTriEx-1, and pTriEx-2 expression vectors.
Methods generally known in the art can be used to transcribe mRNA from the recombinant expression vectors described above. For example, PCR can be performed using the recombinant expression vector as a DNA template to produce a linear DNA template. In vitro transcription of the generated linear DNA template can then be used to generate recombinant CARs and/or recombinant CCR mRNA. Optionally, the linear DNA template is purified prior to performing in vitro transcription.
Nucleic acids encoding recombinant CARs and/or recombinant CCR can be cloned into expression vectors using molecular cloning techniques well known in the art.
Expression vectors comprising recombinant nucleic acids encoding recombinant CARs and/or recombinant CCR can be transferred into T cells using any technique known in the art, such as electroporation, non-viral chemical transfection, and viral transduction. In a particular example, the T cell is genetically modified to express the recombinant CAR and the recombinant CCR by electroporation.
The genetically modified T cells of the invention provide improved T cell proliferation, reduced expression of T cell depletion markers, and enhanced in vivo tumor killing compared to T cells genetically modified to express recombinant NKG2D CARs and recombinant PD-1 Chimeric Switch Receptors (CSRs), as demonstrated by the data provided in the experimental section. In some examples, T cells genetically modified to express recombinant CARs and recombinant CCR are capable of replicating in vivo, resulting in long-term persistence that can lead to sustained tumor control.
In some examples, a medical disease or disorder can be treated by administering a population of T cells as disclosed herein. In some examples, the medical disease or disorder is a cancer or tumor. In another example, there is provided a method of treating cancer or tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a T cell as disclosed herein or a pharmaceutical composition as disclosed herein. In another example, there is provided the use of a pharmaceutically effective amount of a T cell as disclosed herein in the manufacture of a medicament for the treatment of a cancer or tumor. In yet another example, a T cell or a pharmaceutical composition as disclosed herein is provided for use in the treatment of cancer or a tumor. In some examples, the genetically modified T cells for use in treating cancer or tumor are prepared during a course of therapy. Thus, in one example, there is provided a method of treating a cancer or tumor in a subject in need thereof, the method comprising: a) Obtaining T cells from the subject or from a donor different from the subject to be treated; b) Providing i) a recombinant nucleic acid encoding a recombinant Chimeric Antigen Receptor (CAR), wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of a NKG2D receptor; and ii) a recombinant nucleic acid encoding a recombinant Chimeric Costimulatory Receptor (CCR), wherein the recombinant CCR comprises (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) a costimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-L1 specific single-chain variable fragment (scFv); c) Transferring a recombinant nucleic acid encoding a recombinant CAR and a recombinant nucleic acid encoding a recombinant CCR into a T cell to obtain a genetically modified T cell; and d) administering to the subject a pharmaceutically effective amount of the T cells obtained from c). In some other examples, the method further comprises, after step a), culturing the T cells to expand the number of T cells. T cell expansion methods are known in the art and exemplified in the experimental section of the present application.
As used herein, the term "pharmaceutically effective amount" includes within its meaning a sufficient amount of the T cells described herein to provide the desired therapeutic effect, but without toxicity. Ideally, an effective or sufficient amount of the T cells described herein are present in the composition and introduced into the subject to establish a long-term, specific anti-tumor response, reducing the size of the tumor or eliminating the growth or regeneration of the tumor, as compared to what would otherwise result in the absence of such treatment. Ideally, the amount of T cells introduced into the subject results in a reduction in tumor size of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 100% as compared to otherwise identical conditions in the absence of T cells. Required thickness of TThe exact number of cells will vary from subject to subject, depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated (e.g., the stage and/or size of the tumor), the mode of administration, and the like. In general, the concentration of T cells should ideally be sufficient to provide at least about 1X 10 in the subject being treated 6 To about 1X 10 9 (ii) a T cell, even more desirably, about 1X 10 7 To about 5X 10 8 A T cell, although, for example, 5X 10 can be used 8 More than one cell or, for example, 1X 10 7 Any suitable amount below one cell. The dosing regimen may be based on mature cell-based therapy, or alternative continuous infusion strategies may be employed. These values provide general guidance to the practitioner in optimizing the T cell range to be used in the treatment methods disclosed herein. These ranges recited herein in no way preclude the use of higher or lower amounts of the components, which may be warranted in a particular application. For example, the actual dosage and schedule may vary depending on whether the composition is administered in combination with other pharmaceutical compositions, or depending on the inter-individual differences in pharmacokinetics, drug disposition and metabolism. An appropriate "effective amount" in any given case can be determined by one of ordinary skill in the art using only routine experimentation.
Cancers or tumors for which the present treatment methods are useful include any malignant cell type, such as those found in solid tumors or hematological tumors. In some embodiments, the malignant tumor is a solid tumor. Exemplary solid tumors may include, but are not limited to, tumors of organs selected from the group consisting of pancreas, colon, caecum, stomach, brain, head, neck, ovary, kidney, larynx, sarcoma, lung, bladder, melanoma, prostate, and breast. In some embodiments, the malignant tumor is a hematological tumor. Exemplary hematological tumors include bone marrow tumors, T cell or B cell malignancies, leukemias, lymphomas, blastomas, myelomas, and the like. Further examples of cancers that can be treated using the methods provided herein include, but are not limited to, lung cancer (including small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung), cancer of the peritoneum, gastric cancer (including gastrointestinal and gastrointestinal stromal cancer), pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland carcinoma, kidney cancer, prostate cancer, vulval cancer, thyroid cancer, various types of head and neck cancer, and melanoma. The cancer may particularly belong to the following histological types, although not limited to these: neoplasms, malignant; cancer; cancer, undifferentiated; giant cell carcinoma and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphatic epithelial cancer; basal cell carcinoma; hair matrix cancer; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; bile duct cancer; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyps; adenocarcinoma, familial polyposis coli; a solid cancer; carcinoid, malignant; bronchioloalveolar adenocarcinoma; papillary adenocarcinoma; a cancer of the chromophobe; eosinophilic carcinoma; eosinophilic adenocarcinoma; basophilic granulosa cancer; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinomas; non-enveloped sclerosing cancers; adrenocortical carcinoma; endometrial cancer; skin adnexal cancer; hyperhidrosis carcinoma; sebaceous gland cancer; cerumen adenocarcinoma; mucoepidermoid carcinoma; cystic carcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; invasive ductal carcinoma; medullary carcinoma; lobular carcinoma; inflammatory cancer; paget's disease, of the mammary gland; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma with squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecocytoma (thecoma), malignant; granulosa cell tumor, malignant; male cell tumor (androblastoma), malignant; sertoli cell carcinoma; leydig cell tumors, malignant; lipocytoma, malignant; paraganglioma, malignant; external paraganglioma of the breast, malignant; pheochromocytoma; angiosarcoma (glomangiospora); malignant melanoma; non-pigmented melanoma; superficial diffuse melanoma; freckle-like malignant melanoma; acral freckle-like melanoma; nodular melanoma; malignant melanoma in giant pigmented nevi; epithelial-like cell melanoma; blue nevus, malignant; a sarcoma; fibrosarcoma; fibrohistiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; interstitial sarcoma; mixed tumor, malignant; mullerian mixed tumor; nephroblastoma; hepatoblastoma; a carcinosarcoma; stromal tumor, malignant; brenner tumor, malignant; phylloid tumors, malignant; synovial sarcoma; mesothelioma, malignant; clonal cell tumors; an embryonic carcinoma; teratoma, malignant; ovarian goiter (struma ovarii), malignant; choriocarcinoma; mesonephroma, malignant; angiosarcoma; vascular endothelioma, malignant; kaposi's sarcoma; vascular endothelial cell tumor, malignant; lymphangiosarcoma; osteosarcoma; paracortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; ewing's sarcoma; odontogenic tumors, malignant; amelogenic cell dental sarcoma; ameloblastoma, malignant; amelogenic cell fibrosarcoma; pineal tumor, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; a plasma astrocytoma; fibroastrocytoma; astrocytomas; glioblastoma; oligodendroglioma; oligodendroglioma; primitive neuroectoderm; cerebellar sarcoma; ganglionic neuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumors; meningioma, malignant; neurofibrosarcoma; schwannoma, malignant; granulocytoma, malignant; malignant lymphoma; hodgkin's disease; of Hodgkin; granuloma paratuberis; malignant lymphoma, small lymphocytes; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specific non-hodgkin lymphomas; b cell lymphoma; low grade/follicular non-hodgkin lymphoma (NHL); small Lymphocyte (SL) NHL; moderate/follicular NHL; intermediate diffuse NHL; higher immunoblastic NHL; higher lymphoblastic NHL; high-grade small non-lytic cell type NHL; the massive disease NHL (bulk disease NHL); mantle cell lymphoma; AIDS-related lymphoma; waldenstrom's macroglobulinemia; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small bowel disease; leukemia; lymphocytic leukemia; plasma cell leukemia; red leukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryocytic leukemia; myeloid sarcoma; hairy cell leukemia; chronic Lymphocytic Leukemia (CLL); acute Lymphocytic Leukemia (ALL); acute Myeloid Leukemia (AML); and chronic myeloid leukemia. In some examples, cancers/tumors that can be treated using the genetically modified T cells provided herein include colorectal cancer, ovarian cancer, head and neck cancer, liver cancer, breast cancer, cervical cancer, and glioma. In a particular example, the cancer/tumor that can be treated is colorectal cancer.
In some examples, the cancer/tumor expresses both NKG2D ligand and PD-Ll. In some other examples, the cancer/tumor expresses NKG2D ligand and PD-L1 after treatment with another drug, radiation, or biologic agent.
The terms "treat," "treatment," and grammatical variations thereof refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease or to achieve a beneficial or desired clinical result. Such beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; the degree of alleviation of the condition, disorder or disease; a stable state (i.e., not worsening) of the condition, disorder or disease; delay or slowing of progression of the condition, disorder or disease; amelioration, palliation (whether partial or total), whether detectable or undetectable, of a condition, disorder or disease state; or improvement or amelioration of a condition, disorder or disease. Treatment involves the initiation of clinically significant cellular responses without producing excessive levels of side effects. Treatment also includes extending survival as compared to expected survival without treatment.
The terms "reduce," "reduced," "reduce," "decrease," "remove," or "inhibit" are used generically herein to mean a statistically significant amount of reduction. However, for the avoidance of doubt, "reduced", "reduce" or "reduce", "remove" or "inhibit" means a reduction of at least 10% compared to a reference level, such as at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a reduction of 100% (e.g., no level present compared to a reference sample), or any reduction between 10-100% compared to a reference level (e.g., in the absence of a treatment as described herein).
In some examples, the subject or patient to be treated is an animal, mammal, human, including but not limited to animals classified as bovine, porcine, equine, canine, wolf, feline, murine, ovine, avian, fish, caprine, crow, acrine, or delphine. In one example, the patient is a human.
The source of T cells useful for treating a medical disease or disorder can be of any kind, but in specific examples, the cells are obtained from a cord blood bank, a peripheral blood bank, a human embryonic stem cell bank, or an induced pluripotent stem cell bank.
In some examples, T cells useful for treating a medical disease or disorder are autologous, i.e., obtained from the same individual to whom the treatment is to be administered. For example, an autologous source of T cells can be collected from a patient in need of treatment and the T cells activated and modified using methods described herein and known in the art, and then infused back into the patient. Some autologous sources of T cells include PBMCs, cord blood obtained at birth and subsequently stored by the patient, and induced pluripotent stem cells derived from cells obtained from the patient.
In some other examples, T cells useful for treating a medical disease or condition are allogeneic, i.e., derived from a different individual of the same species as the patient, such as a T cell donor. In some other examples, T cells useful for treating a medical disease or condition are xenogeneic, i.e., derived from an animal of a different species than the patient. Genetically modified T cells derived from allogeneic xenogeneic sources may provide a ready-to-use product.
Allogeneic or autologous T cells induce a rapid immune response, but disappear relatively rapidly from circulation due to their limited life span. Thus, concerns about persistent side effects are reduced using the treatment methods disclosed herein.
In certain examples, the T cells described herein are administered in combination with a second therapeutic agent. For example, the second therapeutic agent may include an immunomodulatory agent, a monoclonal antibody, or a chemotherapeutic agent. In a non-limiting example, the immunomodulator is lenalidomide (lenalidomide), the monoclonal antibody is alemtuzumab (alemtuzumab), rituximab (rituxumab), trastuzumab (trastuzumab), ibritumomab (ibritumomab), gemtuzumab (gemtuzumab), adotrantuzumab (brentuximab), adintrantuzumab, blinatunomab (daratumumab), or elozumab (elotuzumab), and the chemotherapeutic agent is fludarabine or cyclophosphamide.
Following administration of the genetically modified T cells disclosed herein for treating or preventing cancer/tumor, the efficacy of the treatment can be assessed in various ways well known to the skilled artisan. For example, one of ordinary skill in the art will appreciate that therapeutic genetically modified cells delivered with a chemical adjuvant are effective in treating or inhibiting cancer in a patient by observing that the therapeutic genetically modified cells reduce the cancer cell burden or prevent a further increase in the cancer cell burden. Cancer cell burden can be measured by methods known in the art, for example, using a polymerase chain reaction assay to detect the presence of certain cancer cell nucleic acids, or using, for example, an antibody assay to detect the presence of markers in a sample (e.g., without limitation, blood) from a subject or patient to identify certain cancer cell markers in the blood, or by measuring the level of circulating cancer cell antibody levels in the patient.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, the terms "comprising," "including," "containing," and the like are to be construed broadly and without limitation. Furthermore, the terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
As used in this application, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a genetic marker" includes a plurality of genetic markers, including mixtures and combinations thereof.
As used herein, the term "about" in the context of concentrations of ingredients of a formulation typically means +/-5% of the stated value, more typically +/-4% of the stated value, more typically +/-3% of the stated value, more typically +/-2% of the stated value, even more typically +/-1% of the stated value, and even more typically +/-0.5% of the stated value.
Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within that range such as 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Certain embodiments may also be broadly and generically described herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the disclosure. This includes the general description of embodiments wherein contingent or negative limitations remove any subject matter from the dependent claims, whether or not the excised material is specifically recited herein.
The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
Other embodiments are within the following claims and non-limiting examples. Further, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.
Experimental part
Method and material
Cell lines and culture conditions
Human K562 myeloid leukemia feeder cells engineered to express CD64, CD86 and CD137L were maintained in IMDM. HepG2 and Detroit-562 were maintained in DMEM. CAOV3 was maintained in RPMI. All types of media were supplemented with 10% FBS (Gibco).
CAR-T cell preparation
Buffy coats of healthy donors were obtained from the Health Sciences Authority (HSA, singapore) under IRB approval and PBMCs thereof were separated using density gradient centrifugation. PBMC were processed at 5X 10 6 The individual cells/ml were inoculated in T cell medium (AIM-V +5% AB serum) and activated with 1. Mu.g/ml of soluble OKT3 (Ebioscience) or TransAct (Miltenyi Biotec, germany) for 2-3 days, every 1X 10 7 Mu.l TransAct was added to each PBMC. Recombinant IL-2 (300 IU/ml; peprotech) was added at the beginning of the culture and supplemented every other day.
On day 2 or 3, activated T cells were collected and transduced by non-viral electroporation. The culture of the modified T cells was continued for 5 days in AIM-V supplemented with 5% AB serum or 1% human plasma and 300IU/ml IL-2. On day 8, the genetically modified T cells were counted and co-cultured with γ -irradiated K562 or K562#6 cells in AIM-V medium supplemented with 300IU/ml IL-2 at a ratio of 1. CAR T cells were re-stimulated every 10 days with the addition of new gamma irradiated K562 cells at a rate of 1. For the proliferation of unmodified T cells, T cells were co-cultured with gamma irradiated K562#6 at a ratio of 1. IL-2 was added at 300IU/ml at the beginning of the culture and supplemented every other day.
CD56+ cells were removed from CAR-T cell cultures on day 17 according to the manufacturer's protocol (Miltenyi Biotec, germany). In short, up to 1X 10 7 Individual cells were suspended in 80. Mu.l of the AutoMACS running buffer and incubated with 20. Mu.l of CD56 microbeads for 15 minutes at 4 ℃ in the absence of light. Cells were centrifuged at 300g for 10 min and resuspended in 500. Mu.l of autoMACS running buffer. The LS column was placed in MACS MultiStand and equilibrated by washing twice with 1ml of autoMACS running buffer. The cell suspension was added to the LS column to capture labeled CD56+ cells. The CD 56-flow through fractions were collected at the bottom of a column in a 15ml conical centrifuge tube (BD Biosciences, USA).
Flow cytometry
For phenotypic analysis of T cells, the following labeled anti-human antibodies were used: CD3 (clone: OKT3; eBioscience), CD45RO (clone: UCHL1; BD Biosciences), CCR7 (clone: 3D12 eBioscience), PD-1 (clone: MIH4; BD Pharmingen), TIGIT (clone: MBSA43; eBioscience), TIM3 (clone: F38-2Ebioscience), and LAG3 (clone: 3DS223H. The circle gate was verified using the appropriate isotype control. THE USE OF THE ON THE 5 th day after electroporation and 12 th day after one week of coculture with gamma irradiated K562#6 TM The nwspqfek tag antibody (Genescript) measures the expression of NKG2D CAR (which includes Strep tag) on T cells. Flow cytometry analysis and use of BD Accuri TM C6 (BD Biosciences) analysis.
In vitro cytotoxicity assay
The cytolytic activity of CAR-modified T cells was examined using the DELFIA EuTDA cytoxicity Reagents kit (PerkinElmer). The ratio of effector to target (E: T) used ranged from 20 to 1. The control group was set to measure spontaneous release (target cells added only), maximum release (target cells added with 10 μ l lysis buffer) and media background (no cells added). The killing efficacy was calculated using the following formula:
% specific release = (experimental release (count) -spontaneous release (count))/(maximum release (count) -spontaneous release (count)) × 100
In vivo experiments
Animal experiments were conducted according to protocols reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Biological Resources Center (BRC) of the science, technology and research institute of singapore (a STAR) (accession number BRC IACUC # 181324). Non-obese diabetic/severe combined immunodeficiency/IL-2R γ cnell (NSG) mice (8-10 weeks old, male, jackson laboratories, usa) were maintained and used in the current study. All luminescence signals and images were collected and analyzed using Xenogen in vivo imaging software v 3.2.
To establish a mouse colorectal cancer (CRC) xenograft model, mice were intraperitoneally injected 2X 10 on day 0 6 Individual HCT116-luc human colorectal cancer cells. Tumor implantation was confirmed by in vivo bioluminescence Imaging (BLI) monitored using the IVIS Spectrum Imaging platform with Living Image software (PerkinElmer) on day 7 post tumor inoculation. Mice with similar BLI signal intensity were randomly divided into 4 different treatment groups of 5 mice each. On day 7, 100. Mu.l PBS or 100. Mu.l containing 1X 10 was injected intraperitoneally 7 Mice were treated with cell suspensions of three different groups of T cells: (1) control T cells, (2) NKG2D CAR + PD-1 CSR double CAR modified T cells, or (3) NKG2D CAR + alpha PD-L1 CCR double CAR modified T cells. Same dose (1X 10) at day 32 after tumor inoculation 7 Individual T cells/mouse) for a second injection. Tumor progression was monitored weekly by BLI. The mice were closely monitored and humanely euthanized after observing the development of an moribund state characterized by significant abdominal distension, palpable hypothermia, inability to walk, and/or lack of significant response to the procedure as induced by ascites.
Statistics of
For in vitro and in vivo experiments, 2 groups of continuous variables were evaluated using unpaired student t-test, and more than 2 groups of continuous variables were evaluated using one-way analysis of variance with post-test Bonferroni. Survival was analyzed by the Kaplan-Meier method and the log rank (Mantel-Cox) test to compare paired groups. Statistics were calculated using GraphPad Prism 7.0 (GraphPad software). When the P value is less than 0.05, the difference is considered significant.
Results
In order to improve the in vivo persistence of tumor-reactive T cells, the use of PD-1 based CSR in combination with tumor-reactive TCRs or CARs has been investigated and validated in several studies. However, PD-1 naturally recognizes both PD-L1 and PD-L2, with the expression pattern of PD-L2 being primarily restricted to myeloid lineage cells, while PD-L1 is more commonly found to be upregulated on various tumors. Therefore, there is a need to further improve the tumor specificity of this approach. In the present invention, a first generation CAR was constructed by fusing the extracellular domain of the NKG2D receptor with the DAP 12-derived activation domain (figure 1A). To specifically target PD-L1, an α PD-L1 CCR was generated that recognized only PD-L1 but not PD-L2 (fig. 1B). At the same time, a PD-1 based CSR was also generated for comparative studies (fig. 1C). In both constructs, the antigen targeting moiety was expressed in tandem with a single co-stimulatory domain derived from 4-1BB. Hereinafter, the combination of NKG2D CAR and α PD-L1 CCR will be referred to as CAR-T1, and the combination of NKG2D CAR and PD-1 CSR will be referred to as CAR-T2.
To assess the function of CAR-T1 and CAR-T2 cells, magnetic bead-activated T cells were co-electroporated with plasmids encoding piggyBac transposase, NKG2D CAR, and alpha PD-L1 CCR or PD-1 CSR. To expand and enrich for NKG2D CAR expressing T cells, these T cells were co-cultured with the human K562 myeloid leukemia cell line at an effector to target (E: T) ratio of 1. Expanded CAR-T1 and CAR-T2 cells were then used as effector cells and their cytotoxicity was assessed in a 2-hour cytotoxicity assay for cancer cells bearing NKG2D and PD-1 ligands. Three different cancer cell lines with different PD-1 ligand expression levels were used: hepG2 only expressed NKG2DL, but not any PD-1 ligand; CAOV3 expresses NGK2DL and PD-L1; detroit-562 expresses NKG2DL and two PD-1 ligands. As shown in FIG. 2, there were no observable statistical differences in cytotoxicity of CAR-T1 and CAR-T2 cells on each of the three target cell lines.
To assess the potential for large-scale production, CAR-T1 and CAR-T2 cells were expanded continuously with a batch of fresh gamma-irradiated K562 feeder cells every 10 days in the presence of IL-2 alone. The increase in cell number was counted over a 30 day period and robust expansion of these CAR-T cells was observed (figure 3). Although there were no observable differences in cytotoxicity between NKG2D CAR-T cells implanted with either alpha PD-L1 CCR or PD-1 CSR, the overall cell yield of CAR-T1 was improved when co-cultured with K562 feeder cells compared to CAR-T2 (figure 3). This trend of improvement was consistent in all three donors tested.
Next, it was evaluated how the incorporation of α PD-L1 CCR could further improve the development of memory T cell subsets. Co-expression of both markers on CAR-T1 and CAR-T2 cells at the mid and end of the expansion phase was assessed using CCR7 and CD45RA as markers for classifying various memory subpopulations. As shown in FIG. 4, memory T cell development differed between the two CAR-T groups. Comparing the T cell composition at the mid-and end-expansion stages, the proportion of effector T cells in CAR-T2 rose slightly from 33.2% to 34.5%, whereas in CAR-T1 this proportion fell from 26.6% to 15.2%. In contrast, the percentage of effector memory T cells decreased from 66.2% to 64.9% in CAR-T2, but increased from 73.3% to 84.6% in CAR-T1. Although there were no detectable levels of central memory T cells or stem cell memory T cells, figure 4 shows a clear difference in effector memory T development between α PD-L1 CCR and PD-1 CSR.
Chronic antigen activation often results in increased expression of typical T cell depletion markers. To investigate how α PD-L1 CCR mitigates expression of T cell depletion markers and possibly reverses T cell fate in an immunosuppressive setting, expression of PD-1, TIGIT, LAG3 and TIM3 on CAR-T1 and CAR-T2 cells was measured at the end of the expansion phase. Consistent with the results seen in figures 3 and 4, CAR-T1 cells exhibited reduced expression levels of these depletion markers compared to CAR-T2 cells (figure 5). The experimental setup did not distinguish between endogenous inhibitory PD-1 receptors and exogenous PD-1 CSR, therefore, higher levels of PD-1 on CAR-T2 may not indicate increased inhibition of PD-1. However, the expression levels of TIGIT, TIM3 and LAG3 were consistently higher on CAR-T2 cells in all three subjects. The single endpoint measurements (fig. 5A) and the summary mean (fig. 5B) from a single donor together indicate that incorporation of α PD-L1 CCR alleviated T cell depletion to a greater extent than PD-1 CSR.
It was further investigated whether there was a difference in tumor killing effect in vivo between CAR-T1 (NKG 2D CAR + α PD-L1 CCR) and CAR-T2 (NKG 2D CAR + PD-1 CSR). We established a mouse colorectal model in NSG mice by intraperitoneal (i.p.) injection of human HCT116-luc CRC cells. Tumor progression was monitored by whole body bioluminescence imaging (fig. 6). On day 7, when all mice had established tumors in the abdominal cavity, animals were randomized into 4 groups for treatment: group 1 was given two intraperitoneal injections of PBS; group 2 two intraperitoneal injections, 10 each 7 Individual control CAR-T cells; group 3 and group 4 received two intraperitoneal injections, 10 each 7 CAR-T1 cells and CAR-T2 cells. As shown in fig. 6, the 4 groups of mice exhibited similar tumor burden on day 7 prior to treatment, as evidenced by similar bioluminescence intensity. Established tumors continued to grow in PBS and control CAR-T cell treated mice, all mice died on day 28. With dual CAR-T treatment, the established tumors were completely eliminated and their bioluminescent signals became undetectable on day 14. By treatment, a significant reduction in disease is maintained>At 8 weeks, by day 62, 4 of 10 treated mice developed tumor regeneration, 3 of the CAR-T2 group, and 1 of the CAR-T1 group. By day 150, while 3 mice died and 2 survived in the CAR-T2 group, all mice in the CAR-T1 group survived well: of these 4 had no tumor and 1 mouse showed stable disease. The Kaplan-Meier curve and log rank test results are shown in fig. 7, indicating that there is a significant difference between the two sets of survival curves. Overall, this animal experiment shows that while both CAR-T1 and CAR-T2 are able to effectively eradicate established solid tumors in vivo, tumor killing efficacy is further significantly enhanced by replacing PD-1 CSR with alpha PD-L1 CCR for dual CAR construction.
Conclusion
Due to their special biological properties, such as clonal heterogeneity and a suppressive Tumor Microenvironment (TME) that is unfavorable for T cells, eradication of large solid tumors remains challenging for most cancer patients.
PD-1 recognizes both PD-L1 and PD-L2. PD-L1 is overexpressed on tumor cells and at low levels on a wide range of non-hematopoietic cells. The expression pattern of PD-L2 is more restricted than PD-L1, and its expression is mainly restricted to antigen presenting cells such as dendritic cells, macrophages, B1B cells and mast cells. Thus, of the two PD-1 ligands, PD-L1 is considered to be the primary mediator of cancer immune evasion, while PD-L2 does not appear to be the primary mediator of T cell inhibition at the tumor site, although PD-L2 may play a role in some cases. Another difference is their affinity for PD-1: PD-L2 has a2 to 6-fold higher affinity for PD-1 than PD-L1 and PD-L2 shows different binding/dissociation kinetics compared to the interaction between PD-1 and PD-L1. These different binding properties of PD-L2 and PD-L1 may be responsible for the different contributions of these two PD-1 ligands to the immune response.
Previous studies have utilized PD-1 receptor-based CSR to protect transduced T cells from PD-L1-induced T cell suppression and to convert inhibitory signals into the required costimulatory signals to achieve optimal T cell function. When used in bispecific dual CAR constructions, the higher binding properties of PD-L2 to PD-1 may lead PD-1-based dual CAR-T cells to be more readily activated by PD-L2 positive cells. To improve cancer specificity and reduce side effects on antigen presenting cells and adverse events associated with PD-1 blockade, PD-L1 specific CSR should be used, which unfortunately is difficult to construct by using the extracellular structure of the PD-1 receptor. To avoid this problem, the present invention utilizes scFv fragments specific for PD-L1 to generate chimeric co-stimulatory receptors (CCR). When used with first generation NKG2D CARs, the use of such anti-PD-L1 CCR based bispecific dual CARs has been demonstrated to improve T cell proliferation, reduce expression of T cell depletion markers, and most importantly, enhance tumor killing in vivo.
As clinical trials based on CAR-T cell therapy continue to fight off on-target tumoricidal effects, immune evasion and immunosuppression, new strategies are needed to supplement ongoing clinical work. As a concluding remark, the bispecific dual CARs developed here offer a conceivably attractive opportunity in different therapeutic regimens targeting PD-L1 and NKG2D ligand-positive cancer types. When a tumor type shows selective overexpression of PD-L1, the use of the presently disclosed dual CARs allows T cells to overcome immunosuppressive TME while activating T cell cytotoxicity against NKG2G ligand-expressing cancer cells. Importantly, this dual specificity dual CAR is theoretically safe and does not pose any potential threat to the patient, thereby paving the way for a smoother transformation application.
Sequence listing
<110> Singapore national university
<120> genetically modified T cell and use thereof
<130> 10104SG1209
<160> 32
<170> PatentIn version 3.5
<210> 1
<211> 150
<212> PRT
<213> Artificial sequence
<220>
<223> extracellular Domain of PD-1
<400> 1
Pro Gly Trp Phe Leu Asp Ser Pro Asp Arg Pro Trp Asn Pro Pro Thr
1 5 10 15
Phe Ser Pro Ala Leu Leu Val Val Thr Glu Gly Asp Asn Ala Thr Phe
20 25 30
Thr Cys Ser Phe Ser Asn Thr Ser Glu Ser Phe Val Leu Asn Trp Tyr
35 40 45
Arg Met Ser Pro Ser Asn Gln Thr Asp Lys Leu Ala Ala Phe Pro Glu
50 55 60
Asp Arg Ser Gln Pro Gly Gln Asp Cys Arg Phe Arg Val Thr Gln Leu
65 70 75 80
Pro Asn Gly Arg Asp Phe His Met Ser Val Val Arg Ala Arg Arg Asn
85 90 95
Asp Ser Gly Thr Tyr Leu Cys Gly Ala Ile Ser Leu Ala Pro Lys Ala
100 105 110
Gln Ile Lys Glu Ser Leu Arg Ala Glu Leu Arg Val Thr Glu Arg Arg
115 120 125
Ala Glu Val Pro Thr Ala His Pro Ser Pro Ser Pro Arg Pro Ala Gly
130 135 140
Gln Phe Gln Thr Leu Val
145 150
<210> 2
<211> 450
<212> DNA
<213> Artificial sequence
<220>
<223> extracellular Domain of PD-1
<400> 2
ccaggatggt tcttagactc cccagacagg ccctggaacc cccccacctt ctccccagcc 60
ctgctcgtgg tgaccgaagg ggacaacgcc accttcacct gcagcttctc caacacatcg 120
gagagcttcg tgctaaactg gtaccgcatg agccccagca accagacgga caagctggcc 180
gccttccccg aggaccgcag ccagcccggc caggactgcc gcttccgtgt cacacaactg 240
cccaacgggc gtgacttcca catgagcgtg gtcagggccc ggcgcaatga cagcggcacc 300
tacctctgtg gggccatctc cctggccccc aaggcgcaga tcaaagagag cctgcgggca 360
gagctcaggg tgacagagag aagggcagaa gtgcccacag cccaccccag cccctcaccc 420
aggccagccg gccagttcca aaccctggtg 450
<210> 3
<211> 136
<212> PRT
<213> Artificial sequence
<220>
<223> extracellular domain of NKG2D receptor
<400> 3
Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro
1 5 10 15
Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe
20 25 30
Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln
35 40 45
Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu
50 55 60
Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr
65 70 75 80
Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu
85 90 95
Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser
100 105 110
Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile
115 120 125
Cys Met Gln Arg Thr Val Ala Ser
130 135
<210> 4
<211> 408
<212> DNA
<213> Artificial sequence
<220>
<223> extracellular domain of NKG2D receptor
<400> 4
ttcaaccaag aagttcaaat tcccttgacc gaaagttact gtggcccatg tcctaaaaac 60
tggatatgtt acaaaaataa ctgctaccaa ttttttgatg agagtaaaaa ctggtatgag 120
agccaggctt cttgtatgtc tcaaaatgcc agccttctga aagtatacag caaagaggac 180
caggatttac ttaaactggt gaagtcatat cattggatgg gactagtaca cattccaaca 240
aatggatctt ggcagtggga agatggctcc attctctcac ccaacctact aacaataatt 300
gaaatgcaga agggagactg tgcactctat gcctcgagct ttaaaggcta tatagaaaac 360
tgttcaactc caaatacgta catctgtatg caaaggactg tggctagc 408
<210> 5
<211> 241
<212> PRT
<213> Artificial sequence
<220>
<223> PD-L1 scFv
<400> 5
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Thr Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser
210 215 220
Asn Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala
225 230 235 240
Ser
<210> 6
<211> 723
<212> DNA
<213> Artificial sequence
<220>
<223> PD-L1 scFv
<400> 6
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc gactatggtt tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcaccgctt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagactac 300
ttctacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc aggtggaggc 360
ggttcaggcg gaggtggcag cggcggtggc gggtcggaaa ttgtgttgac acagtctcca 420
gccaccctgt ctttgtctcc aggggaaaga gccaccctct cctgcagggc cagtcagagt 480
gttagcagct acttagtctg gtaccaacag aaacctggcc aggctcccag gctcctcatc 540
tatgatgcat ccaacagggc cactggcatc ccagccaggt tcagtggcag tgggtctggg 600
acagacttca ctctcaccat cagcagccta gagcctgaag attttgcagt ttattactgt 660
cagcagcgta gcaactggcc tcggacgttc ggccaaggga ccaaggtgga aatcaaagct 720
agc 723
<210> 7
<211> 117
<212> PRT
<213> Artificial sequence
<220>
<223> VH PD-L1 scFv
<400> 7
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Thr Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115
<210> 8
<211> 351
<212> DNA
<213> Artificial sequence
<220>
<223> VH PD-L1 scFv
<400> 8
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc gactatggtt tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcaccgctt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagactac 300
ttctacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc a 351
<210> 9
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> VL PD-L1 scFv
<400> 9
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105
<210> 10
<211> 321
<212> DNA
<213> Artificial sequence
<220>
<223> VL PD-L1 scFv
<400> 10
gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttagc agctacttag tctggtacca acagaaacct 120
ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct 240
gaagattttg cagtttatta ctgtcagcag cgtagcaact ggcctcggac gttcggccaa 300
gggaccaagg tggaaatcaa a 321
<210> 11
<211> 15
<212> PRT
<213> Artificial sequence
<220>
<223> PD-L1 scFv VH and VL linker
<400> 11
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15
<210> 12
<211> 45
<212> DNA
<213> Artificial sequence
<220>
<223> PD-L1 scFv VH and VL linker
<400> 12
ggtggaggcg gttcaggcgg aggtggcagc ggcggtggcg ggtcg 45
<210> 13
<211> 39
<212> PRT
<213> Artificial sequence
<220>
<223> transmembrane domain of CAR
<400> 13
Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Phe Trp Val Leu
1 5 10 15
Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val
20 25 30
Ala Phe Ile Ile Phe Trp Val
35
<210> 14
<211> 117
<212> DNA
<213> Artificial sequence
<220>
<223> transmembrane domain of CAR
<400> 14
gaatctaaat atggcccccc ttgcccacca tgtcccttct gggttttggt agttgtcggc 60
ggggtgcttg cttgctattc attgttggtt acggtggctt ttataatttt ctgggta 117
<210> 15
<211> 83
<212> PRT
<213> Artificial sequence
<220>
<223> transmembrane domain of CCR
<400> 15
Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro
1 5 10 15
Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu
20 25 30
Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg
35 40 45
Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly
50 55 60
Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn
65 70 75 80
His Arg Asn
<210> 16
<211> 249
<212> DNA
<213> Artificial sequence
<220>
<223> transmembrane domain of CCR
<400> 16
ttcgtgccgg tcttcctgcc agcgaagccc accacgacgc cagcgccgcg accaccaaca 60
ccggcgccca ccatcgcgtc gcagcccctg tccctgcgcc cagaggcgtg ccggccagcg 120
gcggggggcg cagtgcacac gagggggctg gacttcgcct gtgatatcta catctgggcg 180
cccttggccg ggacttgtgg ggtccttctc ctgtcactgg ttatcaccct ttactgcaac 240
cacaggaac 249
<210> 17
<211> 52
<212> PRT
<213> Artificial sequence
<220>
<223> intracellular signaling domain of CAR
<400> 17
Tyr Phe Leu Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala Glu Ala
1 5 10 15
Ala Thr Arg Lys Gln Arg Ile Thr Glu Thr Glu Ser Pro Tyr Gln Glu
20 25 30
Leu Gln Gly Gln Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr Gln Arg
35 40 45
Pro Tyr Tyr Lys
50
<210> 18
<211> 156
<212> DNA
<213> Artificial sequence
<220>
<223> intracellular signaling domain of CAR
<400> 18
tacttcctgg gacgacttgt tcctcggggg cggggtgctg cagaagctgc aacgcgaaaa 60
caaagaatta ccgagactga gagtccgtat caagaactgc agggccaaag aagcgacgtt 120
tactccgatc tcaataccca acggccttac tacaaa 156
<210> 19
<211> 47
<212> PRT
<213> Artificial sequence
<220>
<223> Co-stimulatory signaling domains of CCR
<400> 19
Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
1 5 10 15
Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
20 25 30
Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
35 40 45
<210> 20
<211> 141
<212> DNA
<213> Artificial sequence
<220>
<223> Co-stimulatory signaling domains of CCR
<400> 20
cgtttctctg ttgttaaacg gggcagaaag aagctcctgt atatattcaa acaaccattt 60
atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa 120
gaagaaggag gatgtgaact g 141
<210> 21
<211> 26
<212> PRT
<213> Artificial sequence
<220>
<223> Signal peptide
<400> 21
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Gly Ala His Ala
20 25
<210> 22
<211> 78
<212> DNA
<213> Artificial sequence
<220>
<223> Signal peptide
<400> 22
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccaggcg cgcatgcc 78
<210> 23
<211> 284
<212> PRT
<213> Artificial sequence
<220>
<223> CAR without signal peptide
<400> 23
Phe Asn Gln Glu Val Gln Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro
1 5 10 15
Cys Pro Lys Asn Trp Ile Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe
20 25 30
Asp Glu Ser Lys Asn Trp Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln
35 40 45
Asn Ala Ser Leu Leu Lys Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu
50 55 60
Lys Leu Val Lys Ser Tyr His Trp Met Gly Leu Val His Ile Pro Thr
65 70 75 80
Asn Gly Ser Trp Gln Trp Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu
85 90 95
Leu Thr Ile Ile Glu Met Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser
100 105 110
Ser Phe Lys Gly Tyr Ile Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile
115 120 125
Cys Met Gln Arg Thr Val Ala Ser Asn Trp Ser His Pro Gln Phe Glu
130 135 140
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asn Trp Ser His Pro
145 150 155 160
Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asn Trp
165 170 175
Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly
180 185 190
Ser Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Phe Trp Val
195 200 205
Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr
210 215 220
Val Ala Phe Ile Ile Phe Trp Val Tyr Phe Leu Gly Arg Leu Val Pro
225 230 235 240
Arg Gly Arg Gly Ala Ala Glu Ala Ala Thr Arg Lys Gln Arg Ile Thr
245 250 255
Glu Thr Glu Ser Pro Tyr Gln Glu Leu Gln Gly Gln Arg Ser Asp Val
260 265 270
Tyr Ser Asp Leu Asn Thr Gln Arg Pro Tyr Tyr Lys
275 280
<210> 24
<211> 852
<212> DNA
<213> Artificial sequence
<220>
<223> CAR without signal peptide
<400> 24
ttcaaccaag aagttcaaat tcccttgacc gaaagttact gtggcccatg tcctaaaaac 60
tggatatgtt acaaaaataa ctgctaccaa ttttttgatg agagtaaaaa ctggtatgag 120
agccaggctt cttgtatgtc tcaaaatgcc agccttctga aagtatacag caaagaggac 180
caggatttac ttaaactggt gaagtcatat cattggatgg gactagtaca cattccaaca 240
aatggatctt ggcagtggga agatggctcc attctctcac ccaacctact aacaataatt 300
gaaatgcaga agggagactg tgcactctat gcctcgagct ttaaaggcta tatagaaaac 360
tgttcaactc caaatacgta catctgtatg caaaggactg tggctagcaa ctggtcacac 420
ccccagtttg agaaaggtgg gggagggtca ggtggtgggg ggtcaaattg gtctcatccc 480
cagttcgaga agggcggagg aggttcaggt gggggtggga gcaactggag ccaccctcaa 540
tttgaaaaag gaggtggagg gagtggaggt ggtggatctg aatctaaata tggcccccct 600
tgcccaccat gtcccttctg ggttttggta gttgtcggcg gggtgcttgc ttgctattca 660
ttgttggtta cggtggcttt tataattttc tgggtatact tcctgggacg acttgttcct 720
cgggggcggg gtgctgcaga agctgcaacg cgaaaacaaa gaattaccga gactgagagt 780
ccgtatcaag aactgcaggg ccaaagaagc gacgtttact ccgatctcaa tacccaacgg 840
ccttactaca aa 852
<210> 25
<211> 310
<212> PRT
<213> Artificial sequence
<220>
<223> CAR with Signal peptide
<400> 25
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Gly Ala His Ala Phe Asn Gln Glu Val Gln
20 25 30
Ile Pro Leu Thr Glu Ser Tyr Cys Gly Pro Cys Pro Lys Asn Trp Ile
35 40 45
Cys Tyr Lys Asn Asn Cys Tyr Gln Phe Phe Asp Glu Ser Lys Asn Trp
50 55 60
Tyr Glu Ser Gln Ala Ser Cys Met Ser Gln Asn Ala Ser Leu Leu Lys
65 70 75 80
Val Tyr Ser Lys Glu Asp Gln Asp Leu Leu Lys Leu Val Lys Ser Tyr
85 90 95
His Trp Met Gly Leu Val His Ile Pro Thr Asn Gly Ser Trp Gln Trp
100 105 110
Glu Asp Gly Ser Ile Leu Ser Pro Asn Leu Leu Thr Ile Ile Glu Met
115 120 125
Gln Lys Gly Asp Cys Ala Leu Tyr Ala Ser Ser Phe Lys Gly Tyr Ile
130 135 140
Glu Asn Cys Ser Thr Pro Asn Thr Tyr Ile Cys Met Gln Arg Thr Val
145 150 155 160
Ala Ser Asn Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser
165 170 175
Gly Gly Gly Gly Ser Asn Trp Ser His Pro Gln Phe Glu Lys Gly Gly
180 185 190
Gly Gly Ser Gly Gly Gly Gly Ser Asn Trp Ser His Pro Gln Phe Glu
195 200 205
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ser Lys Tyr Gly
210 215 220
Pro Pro Cys Pro Pro Cys Pro Phe Trp Val Leu Val Val Val Gly Gly
225 230 235 240
Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe
245 250 255
Trp Val Tyr Phe Leu Gly Arg Leu Val Pro Arg Gly Arg Gly Ala Ala
260 265 270
Glu Ala Ala Thr Arg Lys Gln Arg Ile Thr Glu Thr Glu Ser Pro Tyr
275 280 285
Gln Glu Leu Gln Gly Gln Arg Ser Asp Val Tyr Ser Asp Leu Asn Thr
290 295 300
Gln Arg Pro Tyr Tyr Lys
305 310
<210> 26
<211> 930
<212> DNA
<213> Artificial sequence
<220>
<223> CAR with Signal peptide
<400> 26
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccaggcg cgcatgcctt caaccaagaa gttcaaattc ccttgaccga aagttactgt 120
ggcccatgtc ctaaaaactg gatatgttac aaaaataact gctaccaatt ttttgatgag 180
agtaaaaact ggtatgagag ccaggcttct tgtatgtctc aaaatgccag ccttctgaaa 240
gtatacagca aagaggacca ggatttactt aaactggtga agtcatatca ttggatggga 300
ctagtacaca ttccaacaaa tggatcttgg cagtgggaag atggctccat tctctcaccc 360
aacctactaa caataattga aatgcagaag ggagactgtg cactctatgc ctcgagcttt 420
aaaggctata tagaaaactg ttcaactcca aatacgtaca tctgtatgca aaggactgtg 480
gctagcaact ggtcacaccc ccagtttgag aaaggtgggg gagggtcagg tggtgggggg 540
tcaaattggt ctcatcccca gttcgagaag ggcggaggag gttcaggtgg gggtgggagc 600
aactggagcc accctcaatt tgaaaaagga ggtggaggga gtggaggtgg tggatctgaa 660
tctaaatatg gccccccttg cccaccatgt cccttctggg ttttggtagt tgtcggcggg 720
gtgcttgctt gctattcatt gttggttacg gtggctttta taattttctg ggtatacttc 780
ctgggacgac ttgttcctcg ggggcggggt gctgcagaag ctgcaacgcg aaaacaaaga 840
attaccgaga ctgagagtcc gtatcaagaa ctgcagggcc aaagaagcga cgtttactcc 900
gatctcaata cccaacggcc ttactacaaa 930
<210> 27
<211> 371
<212> PRT
<213> Artificial sequence
<220>
<223> CCR without signal peptide
<400> 27
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Gly Phe Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Thr Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50 55 60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Tyr Phe Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Gly Gly Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
130 135 140
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
145 150 155 160
Val Ser Ser Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
165 170 175
Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
180 185 190
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
195 200 205
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser
210 215 220
Asn Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Ala
225 230 235 240
Ser Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala
245 250 255
Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
260 265 270
Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
275 280 285
Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
290 295 300
Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
305 310 315 320
Asn His Arg Asn Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu
325 330 335
Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
340 345 350
Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
355 360 365
Cys Glu Leu
370
<210> 28
<211> 1113
<212> DNA
<213> Artificial sequence
<220>
<223> CCR without signal peptide
<400> 28
caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggtta cacctttacc gactatggtt tcagctgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcaccgctt acaatggtaa cacaaactat 180
gcacagaagc tccagggcag agtcaccatg accacagaca catccacgag cacagtctac 240
atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc gagagactac 300
ttctacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc aggtggaggc 360
ggttcaggcg gaggtggcag cggcggtggc gggtcggaaa ttgtgttgac acagtctcca 420
gccaccctgt ctttgtctcc aggggaaaga gccaccctct cctgcagggc cagtcagagt 480
gttagcagct acttagtctg gtaccaacag aaacctggcc aggctcccag gctcctcatc 540
tatgatgcat ccaacagggc cactggcatc ccagccaggt tcagtggcag tgggtctggg 600
acagacttca ctctcaccat cagcagccta gagcctgaag attttgcagt ttattactgt 660
cagcagcgta gcaactggcc tcggacgttc ggccaaggga ccaaggtgga aatcaaagct 720
agcttcgtgc cggtcttcct gccagcgaag cccaccacga cgccagcgcc gcgaccacca 780
acaccggcgc ccaccatcgc gtcgcagccc ctgtccctgc gcccagaggc gtgccggcca 840
gcggcggggg gcgcagtgca cacgaggggg ctggacttcg cctgtgatat ctacatctgg 900
gcgcccttgg ccgggacttg tggggtcctt ctcctgtcac tggttatcac cctttactgc 960
aaccacagga accgtttctc tgttgttaaa cggggcagaa agaagctcct gtatatattc 1020
aaacaaccat ttatgagacc agtacaaact actcaagagg aagatggctg tagctgccga 1080
tttccagaag aagaagaagg aggatgtgaa ctg 1113
<210> 29
<211> 397
<212> PRT
<213> Artificial sequence
<220>
<223> CCR with signal peptide
<400> 29
Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15
Ala Phe Leu Leu Ile Pro Gly Ala His Ala Gln Val Gln Leu Val Gln
20 25 30
Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys
35 40 45
Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Gly Phe Ser Trp Val Arg
50 55 60
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Thr Ala Tyr
65 70 75 80
Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met
85 90 95
Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Arg Ser Leu
100 105 110
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Phe Tyr
115 120 125
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly
130 135 140
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile
145 150 155 160
Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg
165 170 175
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Val
180 185 190
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp
195 200 205
Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly
210 215 220
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp
225 230 235 240
Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg Thr Phe
245 250 255
Gly Gln Gly Thr Lys Val Glu Ile Lys Ala Ser Phe Val Pro Val Phe
260 265 270
Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro
275 280 285
Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys
290 295 300
Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala
305 310 315 320
Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu
325 330 335
Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Phe
340 345 350
Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
355 360 365
Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
370 375 380
Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
385 390 395
<210> 30
<211> 1191
<212> DNA
<213> Artificial sequence
<220>
<223> CCR with Signal peptide
<400> 30
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacacccagc attcctcctg 60
atcccaggcg cgcatgccca ggttcagctg gtgcagtctg gagctgaggt gaagaagcct 120
ggggcctcag tgaaggtctc ctgcaaggct tctggttaca cctttaccga ctatggtttc 180
agctgggtgc gacaggcccc tggacaaggg cttgagtgga tgggatggat caccgcttac 240
aatggtaaca caaactatgc acagaagctc cagggcagag tcaccatgac cacagacaca 300
tccacgagca cagtctacat ggagctgagg agcctgagat ctgacgacac ggccgtgtat 360
tactgtgcga gagactactt ctacggtatg gacgtctggg gccaagggac cacggtcacc 420
gtctcctcag gtggaggcgg ttcaggcgga ggtggcagcg gcggtggcgg gtcggaaatt 480
gtgttgacac agtctccagc caccctgtct ttgtctccag gggaaagagc caccctctcc 540
tgcagggcca gtcagagtgt tagcagctac ttagtctggt accaacagaa acctggccag 600
gctcccaggc tcctcatcta tgatgcatcc aacagggcca ctggcatccc agccaggttc 660
agtggcagtg ggtctgggac agacttcact ctcaccatca gcagcctaga gcctgaagat 720
tttgcagttt attactgtca gcagcgtagc aactggcctc ggacgttcgg ccaagggacc 780
aaggtggaaa tcaaagctag cttcgtgccg gtcttcctgc cagcgaagcc caccacgacg 840
ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc 900
ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc 960
tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg 1020
gttatcaccc tttactgcaa ccacaggaac cgtttctctg ttgttaaacg gggcagaaag 1080
aagctcctgt atatattcaa acaaccattt atgagaccag tacaaactac tcaagaggaa 1140
gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact g 1191
<210> 31
<211> 57
<212> PRT
<213> Artificial sequence
<220>
<223> ST2 tag
<400> 31
Asn Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly Ser Gly Gly
1 5 10 15
Gly Gly Ser Asn Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Gly
20 25 30
Ser Gly Gly Gly Gly Ser Asn Trp Ser His Pro Gln Phe Glu Lys Gly
35 40 45
Gly Gly Gly Ser Gly Gly Gly Gly Ser
50 55
<210> 32
<211> 171
<212> DNA
<213> Artificial sequence
<220>
<223> ST2 tag
<400> 32
aactggtcac acccccagtt tgagaaaggt gggggagggt caggtggtgg ggggtcaaat 60
tggtctcatc cccagttcga gaagggcgga ggaggttcag gtgggggtgg gagcaactgg 120
agccaccctc aatttgaaaa aggaggtgga gggagtggag gtggtggatc t 171
ctacggtatg gacgtctggg gccaagggac cacggtcacc 420
gtctcctcag gtggaggcgg ttcaggcgga ggtggcagcg gcggtggcgg gtcggaaatt 480
gtgttgacac agtctccagc caccctgtct ttgtctccag gggaaagagc caccctctcc 540
tgcagggcca gtcagagtgt tagcagctac ttagtctggt accaacagaa acctggccag 600
gctcccaggc tcctcatcta tgatgcatcc aacagggcca ctggcatccc agccaggttc 660
agtggcagtg ggtctgggac agacttcact ctcaccatca gcagcctaga gcctgaagat 720
tttgcagttt attactgtca gcagcgtagc aactggcctc ggacgttcgg ccaagggacc 780
aaggtggaaa tcaaagctag cttcgtgccg gtcttcctgc cagcgaagcc caccacgacg 840
ccagcgccgc gaccaccaac accggcgccc accatcgcgt cgcagcccct gtccctgcgc 900
ccagaggcgt gccggccagc ggcggggggc gcagtgcaca cgagggggct ggacttcgcc 960
tgtgatatct acatctgggc gcccttggcc gggacttgtg gggtccttct cctgtcactg 1020
gttatcaccc tttactgcaa ccacaggaac cgtttctctg ttgttaaacg gggcagaaag 1080
aagctcctgt atatattcaa acaaccattt atgagaccag tacaaactac tcaagaggaa 1140
gatggctgta gctgccgatt tccagaagaa gaagaaggag gatgtgaact g 1191
<210> 31
<211> 57
<212> PRT
<213> Artificial sequence
<220>
<223> ST2 tag
<400> 31
Asn
Claims (14)
1. A T cell genetically modified to express:
i) A recombinant Chimeric Antigen Receptor (CAR) comprising (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of the NKG2D receptor; and
ii) a recombinant chimeric co-stimulatory receptor (CCR) comprising (a) an extracellular domain comprising an antigen binding region, (b) a transmembrane domain, (c) a co-stimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-L1 specific single chain variable fragment (scFv).
2. The T cell of claim 1, wherein the extracellular domain of the recombinant CAR is the extracellular domain of NKG2D receptor, and/or wherein the extracellular domain of the recombinant CCR is a PD-L1 specific scFv.
3. The T cell of claim 1 or 2, wherein the intracellular signaling domain of the recombinant CAR is CD3 ζ or DAP12.
4. The T cell of any one of claims 1 to 3, wherein the co-stimulatory signaling domain of the recombinant CCR is 4-1BB or CD28.
5. The T cell of any one of claims 1 to 4, wherein the transmembrane domain of the recombinant CAR and the transmembrane domain of the CCR are different.
6. A pharmaceutical composition comprising a pharmaceutically effective amount of T cells according to any one of claims 1 to 5 and a pharmaceutically acceptable excipient.
7. A method of making the T cell of any one of claims 1 to 5, the method comprising:
a) Obtaining or providing a T cell;
b) Providing i) a recombinant nucleic acid encoding a recombinant CAR; and ii) a recombinant nucleic acid encoding a CCR; and
c) Transferring a recombinant nucleic acid encoding the recombinant CAR and a recombinant nucleic acid encoding the CCR into the T cell.
8. A method of treating cancer or tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of the T cell of any one of claims 1 to 5 or the pharmaceutical composition of claim 6.
9. The method of claim 8, wherein the T cells are derived from allogeneic cells or autologous cells.
10. A method of treating a cancer or tumor in a subject in need thereof, the method comprising:
a) Obtaining T cells from the subject or a donor different from the subject to be treated;
b) Providing i) a recombinant nucleic acid encoding a recombinant Chimeric Antigen Receptor (CAR), wherein the recombinant CAR comprises (a) an extracellular domain comprising an antigen-binding region, (b) a transmembrane domain, and (c) an intracellular signaling domain, wherein the recombinant CAR does not comprise a costimulatory signaling domain, and wherein the extracellular domain of the recombinant CAR comprises the extracellular domain of a NKG2D receptor; and ii) a recombinant nucleic acid encoding a recombinant chimeric co-stimulatory receptor (CCR), wherein the recombinant CCR comprises (a) an extracellular domain comprising an antigen binding region, (b) a transmembrane domain, and (c) a co-stimulatory signaling domain, wherein the recombinant CCR does not comprise an intracellular signaling domain, and wherein the extracellular domain of the recombinant CCR comprises a PD-1L1 specific single-chain variable fragment (scFv);
c) Transferring a recombinant nucleic acid encoding the recombinant CAR and a recombinant nucleic acid encoding the recombinant CCR into the T cell to obtain a genetically modified T cell; and
d) Administering to the subject a pharmaceutically effective amount of the T cells obtained from c).
11. The method of any one of claims 8 to 10, wherein the cancer or tumor is a solid tumor.
12. The method of any one of claims 8 to 11, wherein the cancer or tumor expresses both NKG2D ligand and PD-L1.
13. The method of any one of claims 8 to 12, wherein the cancer or tumor is colorectal cancer or colorectal tumor.
14. The method of any one of claims 7 and 10-13, wherein transferring the recombinant nucleic acid in step c) is performed using electroporation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201909544Y | 2019-10-11 | ||
SG10201909544YA SG10201909544YA (en) | 2019-10-11 | 2019-10-11 | Genetically Modified T Cells And Uses Thereof |
PCT/SG2020/050573 WO2021071431A1 (en) | 2019-10-11 | 2020-10-09 | Genetically modified t cells and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115461061A true CN115461061A (en) | 2022-12-09 |
CN115461061B CN115461061B (en) | 2024-07-12 |
Family
ID=75438331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080083339.6A Active CN115461061B (en) | 2019-10-11 | 2020-10-09 | Genetically modified T cells and uses thereof |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN115461061B (en) |
SG (1) | SG10201909544YA (en) |
WO (1) | WO2021071431A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116925236A (en) * | 2023-05-12 | 2023-10-24 | 上海恩凯细胞技术有限公司 | Chimeric transition receptors and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170204372A1 (en) * | 2014-07-15 | 2017-07-20 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
US20190119638A1 (en) * | 2016-04-15 | 2019-04-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
-
2019
- 2019-10-11 SG SG10201909544YA patent/SG10201909544YA/en unknown
-
2020
- 2020-10-09 CN CN202080083339.6A patent/CN115461061B/en active Active
- 2020-10-09 WO PCT/SG2020/050573 patent/WO2021071431A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170204372A1 (en) * | 2014-07-15 | 2017-07-20 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
US20190119638A1 (en) * | 2016-04-15 | 2019-04-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
CN109790517A (en) * | 2016-04-15 | 2019-05-21 | 纪念斯隆-凯特林癌症中心 | Transgenic T cells and Chimeric antigen receptor T cell composition and correlation technique |
Non-Patent Citations (1)
Title |
---|
王健;曹伟娅;李存娣;: "NKG2D配体表达及其介导NK细胞抗肝细胞癌作用的研究进展", 细胞与分子免疫学杂志, no. 07, 18 July 2018 (2018-07-18) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116925236A (en) * | 2023-05-12 | 2023-10-24 | 上海恩凯细胞技术有限公司 | Chimeric transition receptors and uses thereof |
CN116925236B (en) * | 2023-05-12 | 2024-06-04 | 上海恩凯细胞技术有限公司 | Chimeric transition receptors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
SG10201909544YA (en) | 2021-05-28 |
WO2021071431A1 (en) | 2021-04-15 |
CN115461061B (en) | 2024-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021203481B2 (en) | Chimeric antigen receptors (CARs), compositions and methods of use thereof | |
CN111247168B (en) | Composite chimeric antigen receptor (cCAR) targeting multiple antigens and methods of making and using same | |
US9272002B2 (en) | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting | |
JP2023123445A (en) | Methods and compositions for modified t cells | |
US20170296623A1 (en) | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN | |
CN109562126A (en) | Chimeric antigen receptor (CAR), composition and its application method | |
CA3047999A1 (en) | Engineered t cells for the treatment of cancer | |
CA2997749A1 (en) | Ny-eso-1 specific tcrs and methods of use thereof | |
KR20150128997A (en) | Compositions and methods for immunotherapy | |
CA2974434A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
EP2904106A2 (en) | Compositions and methods for targeting stromal cells for the treatment of cancer | |
CN109468279A (en) | Target immune effector cell and its application of GPC3 | |
CN112142854A (en) | Immune regulation specific chimeric antigen receptor cell and preparation method and application thereof | |
KR20180050413A (en) | Methods of Redirecting T Cells to Treat HIV Infection | |
CN108866003A (en) | Genetically engineered cell and application | |
TW201840845A (en) | Methods to protect transplanted tissue from rejection | |
AU2020418199A1 (en) | Modified immune effector cell and preparation method therefor | |
US20210246221A1 (en) | Chimeric antigen receptor targeting sialyl lewis a and uses thereof | |
WO2017011316A1 (en) | Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor | |
US20220184129A1 (en) | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins | |
KR20220038399A (en) | Compositions and methods for borrowing immunotherapy | |
CN114828862A (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
CN117377682A (en) | Selective stimulation of T cells in solid tumors using oncolytic virus delivery of orthogonal IL-2 | |
CN115461061B (en) | Genetically modified T cells and uses thereof | |
KR20240005865A (en) | Combination of PRAME-specific T cell receptor and chimeric co-stimulatory receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |